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Abstract 
Introduction 
The Bordetella bacteria, such as B. pertussis, B. parapertussis and B. holmesii, are 
causative agents of whooping cough in humans. While B. pertussis is well 
documented to be an important agent of this disease in Australia, the roles of B. 
parapertussis and B. holmesii are unknown.  
Aim 
1) To develop specific and sensitive PCR tests for B. parapertussis and B. holmesii  
2) To investigate the incidence of infection of B. parapertussis and B. holmesii 
compared to that of B. pertussis in patients of The Children’s Hospital at 
Westmead 
Methods 
PCR assays for B. parapertussis and B. holmesii were developed and combined with 
the existing in-house PCR test for B. pertussis to form a multiplex assay. The 
insertion sequences IS481, pIS1001 and hIS1001 were used as targets for B. 
pertussis, B. parapertussis and B. holmesii, respectively. Inhibitor control for each 
target was also synthesized and included in the multiplex PCR assay to detect false 
negative results. In this project, total of 464 respiratory tract specimens, mainly 
nasopharyngeal aspirates and swabs, collected from children admitted to the Hospital 
in 2013 were tested using the multiplex PCR. 
Results 
The specificities and sensitivities of the multiplex PCR assay for the three Bordetella 
species were confirmed. A total of 464 specimens were tested by multiplex PCR 
assay, in the period of January to December 2013. Among 25 positive cases of 
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Bordetella, 12 (48%) were positive for B. pertussis, 12 (48%) for B. parapertussis 
and none for B. holmesii. One (4%) case of co-infection with B. pertussis and  
B. parapertussis was detected in these specimens. 
Conclusion 
We have developed a highly specific and sensitive multiplex PCR assay for the three 
Bordetella species causing whooping cough in humans. Using this assay, we show 
that the infection rates of B. pertussis and B. parapertussis to be similar in children 
with respiratory disease. B. holmesii infection is rare in this study group. 
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                                 Chapter 1 Introduction 
1.1 Whooping Cough 
Whooping cough is a severe respiratory disease caused by infection with Bordetella 
species. These are highly contagious, Gram-negative coccobacilli (Figure 1.1) which 
infect the respiratory tract and are transmitted through respiratory droplets generated 
with coughing (1). The first medical chronicle of whooping cough was recorded in 
Paris, France, in 1578, with the illness named as “pertussis” in 1679 (1). Prior to the 
advent of a vaccine for B. pertussis, whooping cough was a major childhood disease 
with severe morbidity and mortality among infants (1). Average reported cases of 
whooping cough in the pre-vaccine era were 157 per 100,000 population in the 
United States. After introducing pertussis whole cell vaccine in the 1940s, the 
average number of cases reduced to 1 per 100,000 population in 1973 (12). However, 
whooping cough is still present with epidemics every 3-5 years (4). In the 1990s, 
there were an estimated 50 million cases per annum worldwide, with approximately 
300,000 deaths (35). 
Recently, the resurgence of whooping cough has been reported in the United States.  
The major epidemics were in 2005 and 2010 with more than 25,000 and 27,000 
reported cases, respectively. There were 9000 cases and 10 deaths of infants reported 
in California in the 2010 epidemic (13). This increased incidence could be due to 
vaccine failure. Factors such as low or no immunity due to lack of primary vaccine 
coverage and failure to administer booster vaccinations  to adolescents and adults as 
well as the lack of awareness of the clinical illness might also contribute to increased 
transmission of the disease (1, 24).  
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1.2 Bordetella Species  
 
The genus Bordetella consists of nine different species, namely B. pertussis, B. 
parapertussis, B. parapertussisov (ovine adapted), B. holmesii, B. bronchiseptica, B. 
petrii, B. hinzii, B. avium, B. trematum and B. ansorpii (Table 1.1). They mainly 
infect the respiratory tract of mammals, birds and reptiles, causing respiratory 
diseases. In humans, B. pertussis, B. parapertussis and B. holmesii are the main 
causative agents of whooping cough (1) 
 
Table 0.1 Characteristics of Bordetella Species 
Bordetella species Host Site of isolation Disease 
B. pertussis Humans Respiratory tract Whooping cough 
B. parapertussis Humans, 
sheep 
Respiratory tract Mild whooping cough 
B. holmesii Humans Respiratory tract, 
blood 
Mild whooping cough, 
septicaemia, 
bacteraemia, 
endocarditis and 
pneumonia 
B. bronchiseptica Humans, 
dogs, pigs, 
rabbits, 
horses, 
sheep, 
mice 
Respiratory tract, 
blood 
Acute or chronic 
bronchopneumonia, 
atrophic rhinitis in 
piglets, kennel cough in 
dog  
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B. petrii Humans Respiratory tract, 
ear, bone  
Bronchiectasis, 
suppuratives 
mastoiditis, mandibular 
osteomyelitis   
B. hinzii Birds,  
humans 
Respiratory tract, 
blood, biliary  
Septicaemia, chronic 
cholangitis (in liver 
transplant recipient) 
B. avium Birds, 
reptiles, 
humans 
Respiratory tract Tracheobronchitis in 
birds, pneumonia in 
humans 
B. trematum Humans Leg ulcer Foot infection in 
diabetic patient 
B. ansorpii Humans Purulent exudate 
of the posterior 
neck   
Epidermal cyst  
 (36, 37, 39, 40, 48, 47, 42, 43). 
 
 
1.2.1 Bordetella pertussis   
 
B. pertussis (Figure 1.1) is the major causative agent of whooping cough in humans. 
It was first isolated in laboratory culture by Bordet and Gengou in 1906, although 
they had observed the bacterium microscopically in the sputum of a patient in 1900. 
B. pertussis is a strict human pathogen which causes severe whooping cough, 
particularly in infants. The infection is generally localized in the upper respiratory 
tract and believed to be caused by the toxins, adhesins and many other factors 
produced by the bacterium (Section 1.3). Currently, it is the only Bordetella species 
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with a targeted vaccine (1). Introduction of B. pertussis whole cell and acellular 
vaccines had significantly reduced the incidence of whooping cough worldwide (3).  
 
Figure 0.1 Bordetella pertussis is a small, Gram-negative, rod-shaped encapsulate bacterium, 
arranged singly or in small groups. (http://www.cdc.gov/pertussis/clinical/disease-specifics.html). 
 
1.2.2 Bordetella parapertussis 
B. parapertussis is another important causative agent of whooping cough in humans, 
second to B. pertussis. It was first isolated in 1930s, by Eldering and Kendrick and 
by Bradford and Slavin from children with suspected whooping cough (1). Two 
different strains of B. parapertussis have been isolated, one from humans and one 
from sheep. The strain that causes whooping cough in humans appears to be specific 
and no transmission of the disease between humans and sheep has been reported (2). 
The infection caused by B. parapertussis is reported to be milder than that caused by 
B. pertussis and more common among children under 5 years (2). B. parapertussis 
also produces some of the toxins and adhesins found in B. pertussis (Section 1.3). 
Unlike B. pertussis, no vaccine has been developed for B. parapertussis (1).  
 
1.2.3 Bordetella holmesii 
B. holmesii was first described in 1995. It was originally identified as a member of 
the Centres for Disease Control and Prevention nonoxidizer group 2 bacteria (20). 
The bacterium is mainly associated with bacteraemia, endocarditis and pneumonia, 
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and has been isolated from blood and sputum samples from patients with disorders 
such as sickle cell anaemia and asplenia. B. holmesii is the most recently identified 
Bordetella species associated with respiratory tract infection in humans in different 
geographical locations. It appears to be an opportunistic pathogen causing whooping 
cough-like epidemics; however, the transmission of B. holmesii between humans 
remains controversial (20). Unlike B. pertussis and B. parapertussis, B. holmesii 
does not produce any of the toxin and adhesins during infection (Section 1.3). Like 
B. parapertussis, no vaccine for B. holmesii has been developed. The B. pertussis 
vaccines have little or no cross protection against B. holmesii (25).  
 
1.2.4 Bordetella bronchiseptica 
B. bronchiseptica, a close evolutionary progenitor of B. pertussis and B. 
parapertussis, is the main causative agent of whooping cough like illness in a wide 
range of mammals. It has also occasionally been isolated from humans who were 
immunocompromised or had close contact with domestic animals (5). 
 
1.2.5 Other Bordetella species 
Other Bordetella species such as B. petrii, B. hinzii, B. avium, B. trematum, and B. 
ansorpii   have been isolated from immunocompromised patients. However, their 
roles in respiratory tract infection in humans remain unclear. (1) 
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1.3 Pathogenicity of B. pertussis, B. parapertussis and B. holmesii 
Virulence factors produced by Bordetella species are divided into two groups: 
adhesins and toxins (Table 1.2). Adhesins includes filamentous hemagglutinin 
(FHA), fimbriae (FIM), pertactin (PRN) and tracheal colonization factor (TCF). 
These factors facilitate the attachment of the bacterium to the cilia of epithelial cells 
and colonize the respiratory tract (Figure 1.2). A number of toxins produced by 
Bordetella species, such as pertussis toxin (PT), adenylate cyclase toxin (AC), 
dermonecrotic toxin (DNT) and tracheal cytotoxin (TCT), destroy ciliated epithelial 
cells in the respiratory tract and cause apoptosis (1,2).  
Table 0.2 Virulence factors produces by Bordetella species 
Virulence factors Bordetella species 
Adhesins B. 
pertussis 
B. 
parapertussis 
B. 
holmesii 
Filamentous hemagglutinin + + - 
Fimbriae + + - 
Pertactin + + - 
Tracheal colonization factor + - - 
Bordetella resistant to kill 
(Brk) protein 
+ ? - 
Toxins 
Pertussis toxin + - - 
Adenylate cyclase toxin + + - 
Dermonecrotic toxin + + - 
Tracheal cytotoxin + + - 
(2, 35, 36, 37, 38) 
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Figure 0.2 Respiratory tract lumen infected with B. pertussis, shows the attachment of bacteria to the 
ciliated epithelial cells via filamentous hemagglutinin and pertussis toxin. This figure is adapted from 
CMAG 2005; 172(4): 509-15 
 
1.3.1 Adhesins  
1.3.1.1 Filamentous Hemagglutinin 
Filamentous hemagglutinin (FHA) is considered to be a major adhesin found in B. 
pertussis and B. parapertussis (Table 1.2). It is of 230kDa in size and with a rod-like 
structure. It functions in conjunction with other adhesins enabling binding to the 
ciliated epithelial cells in the upper respiratory tract and macrophages. This protein 
has the ability to induce both systemic and mucosal antibody responses during 
infection (56). 
1.3.1.2 Fimbriae  
Fimbriae (Fim) is another adhesin found in B. pertussis and B. parapertussis (Table 
1.2), which plays a major role in binding to the epithelial cells and macrophages of 
the upper respiratory tract. It has two serotypes: serotype 2 and 3, which consist of a 
minor fimbrial subunit Fim1 (40kDa) and two different major subunits Fim2 
(22.5kDa) and Fim3 (22kDa), respectively. Fim works in cooperation with FHA to 
enable B. pertussis and B. parapertussis to bind and penetrate into host cells (55).  
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 1.3.1.3 Pertactin 
Pertactin (PRN) is an outer membrane protein (69kDa) found in B. pertussis and B. 
parapertussis (Table 1.2). It participates in the mechanism of adhesion of the 
bacterium to epithelial cells. PRN is polymorphic and has slightly different 
molecular weights in different Bordetella strains (55).  
1.3.1.4 Tracheal Colonization Factor  
Tracheal colonization factor (TCF) is produced only by B. pertussis (Table 1.2) and 
it is mainly involved in colonization of the trachea. It has two forms: a large cell-
associated form (90kDa) and small secreted form (60kDa). It is structurally similar to 
PRN, and hence may have similar functional properties (55). 
1.3.1.5 Bordetella Resistant to Kill Protein    
Bordetella resistant to kill (Brk) protein is an outer membrane protein (103kDa) 
produced and secreted only by B. pertussis (Table 1.2). The presence of Brk protein 
in B. parapertussis has not been clearly identified. This protein protects the 
Bordetella bacterium from killing by serum. It may also be involved in the 
mechanism of adhesion (55). 
 
1.3.2 Toxins 
1.3.2.1 Pertussis Toxin  
Pertussis toxin (PTX) is a protein toxin produced specifically by B. pertussis (Table 
1.2), which causes lymphocytosis by impairing the immune effector cells (2). It 
consists of five different subunits named S1 to S5. The S1 subunit is responsible for 
ADP-ribosyltransferase activity during infection, leading to deregulation of 
metabolic pathways and death of target cells. The S2 to S5 subunits are responsible 
for interaction of the pertussis toxin with the receptors of the target cells (55). It is 
noteworthy that B. parapertussis and B. holmesii do not produce PTX. However, 
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these two bacteria cause a similar illness to that caused by B. pertussis, except for the 
lack of lymphocytosis (1, 2). Thus, the role of PTX in Bordetella pathogenicity 
remains controversial.  
1.3.2.2 Adenylate Cyclase Toxin                                             
Adenylate cyclase toxin (AC) is a bifunctional protein, expressing haemolytic and 
calmodulin-dependent adenylate cyclase activity. It is produced by B. pertussis and 
B. parapertussis (Table 1.2), and is responsible for induction of macrophage 
apoptosis in the early stages of infection. Both haemolytic and enzymatic activities of 
the toxin are required to induce apoptosis (55).  
1.3.2.3 Dermonecrotic Toxin  
Dermonecrotic toxin (DNT) is found in B. pertussis and B. parapertussis. However, 
the toxin does not play a major role in human infection. Most of the human clinical 
isolates appear not to produce DNT. Unlike the other Bordetella toxins, DNT is not 
actively secreted by the bacteria. It can produce dermonecrotic lesions and 
inflammation in the colonized area in the respiratory tract (55).      
1.3.2.4 Tracheal Cytotoxin       
Tracheal cytotoxin (TCT) is a glycopeptide found in the cell wall of B. pertussis and 
B. parapertussis. It causes damage to ciliated epithelial cells in the respiratory tract 
and eventual extrusion of them (55).        
Despite extensive studies on the function of the Bordetella species virulence factors 
and their roles in the disease development are not fully understood. It is well known 
that although B. parapertussis and B. holmessi produce only some of these factors 
(Table 1.2), they have similar pathogenic properties to those of B. pertussis. 
Interaction of these virulence factors among themselves and/or with other unknown 
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factors in the pathogenicity of Bordetella species would be an area for future 
research (2).   
 
1.4 Clinical Features of Whooping Cough 
Clinical manifestations of B. pertussis infection include paroxysmal cough, vomiting, 
convulsions and death (1). Symptoms caused by B. parapertussis and B. holmesii 
tend to be less severe and of a shorter duration than those caused by B. pertussis (17). 
Infections of B. pertussis and B. parapertussis are more common among infants and 
young children, while B. holmesii infection is more frequently found in adolescent 
and adults (16). Clinical manifestations of these three infections vary depending on 
patient age, vaccination status, previous infections and antibiotic treatment (1).  
Average incubation period of Bordetella infection is 7-10 days after the exposure, 
and illness may last for 6-12 weeks or longer. The illness occurs in three stages: 
catarrhal, paroxysmal and convalescent. In the catarrhal stage, the disease begins like 
the common cold, lasting for 1-2 weeks with rhinorrhoea, mild cough and 
occasionally a mild temperature. The paroxysmal stage is characterised by 
uncontrollable coughing, often followed by an inspiratory whoop. Post-tussive 
vomiting is more common in this stage and weight loss may occur due to frequent 
vomiting and refusing food. Complications of classic whooping cough infection 
include pneumonia, seizures and otitis media. Infections in infants are usually more 
severe with apnoea, cyanosis and pulmonary hypertension that may lead to death. 
This stage usually lasts for 2-8 weeks or longer. The convalescent stage is the 
recovery stage. In this stage the cough starts lessening and the other symptoms 
gradually disappear. This stage lasts for 1-2 weeks or longer. Newborn infants are 
more susceptible to B. pertussis infection due to the lack of trans-placental immunity 
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acquired from the mother and vaccination is not commenced until 2 months of age 
(1). 
Mild whooping cough-like illnesses are more common in previously vaccinated or 
infected children, adolescents, and adults with symptoms such as fever, cough or sore 
throat. Cases of whooping cough-like illness may be due to Bordetella species other 
than B. pertussis. B. parapertussis causes mild or classic whooping cough which is 
more common among children under the age of five years and represents 2-20% of 
whooping cough cases (3). The outbreak of a whooping cough-like illness in Ohio 
2010-2011 showed the emergence of B. holmesii infection among the community, 
with B. holmesii infection identified in 29% of all whooping cough cases (16). 
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1.5 Immunity and Vaccination 
Immunity to whooping cough can be acquired by natural infection or vaccination. It 
may only last for 6 to 10 years. Neither infection nor immunization provides lifelong 
immunity to the recurrent infection. As immunity decreases, reinfection can occur, 
which may produce milder symptoms than primary infection with the possibility of 
transmitting the bacterium to other susceptible individuals (3). 
Severe morbidity and mortality due to B. pertussis infection among young children 
has driven vigorous development of vaccines for both treatment and prevention of 
the disease. In 1930s, many candidate vaccines were developed. These initial 
vaccines consisted of washed or unwashed killed whole cell B. pertussis; B. pertussis 
mixed with the other bacteria in the upper respiratory tract and fractionated vaccines 
made from extracted products of B. pertussis. In mid 1940s, whole cell vaccine for B. 
pertussis was introduced into the community for the first time in the United States. 
The vaccine was a combination of diphtheria toxoid, tetanus toxoid and pertussis 
(DTP). Introduction of whole cell pertussis vaccine, in developed countries, has led 
to a dramatic reduction in morbidity and mortality among infants and young children. 
It has also decreased transmission of the disease from children to children and 
adults/adolescents to children thus reducing the intensity of epidemics (1). 
All whole cell pertussis vaccines contain endotoxin and other active toxins, which 
are responsible for post vaccine reactions and adverse events such as an Arthus 
reaction. Local and systemic reactions occurring after the vaccination are dose 
dependent. Local reactions such as redness, pain and swelling are more frequent, 
whereas systemic reactions, except fever, were less frequent in increasing doses.  
Persistent fever is directly correlated with the content of endotoxin (22). Therefore, 
the reactions vary with different production batches.  A study of 13 candidate 
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vaccines in the United States showed that local reactions and systemic reactions such 
as fever, drowsiness, and fussiness were all more frequently found in whole cell 
pertussis (DTwP) vaccine recipients than in acellular pertussis (DTaP) vaccine 
recipients (1). 
Immunization of children with DTwP vaccine in the United States discontinued after 
replacement with the DTaP vaccine in late 1990s. The first DTaP vaccine was 
developed at the National Institutes of Health in Japan in late 1970s. This vaccine 
contains purified antigens from B. pertussis such as FHA, PT, PRN and/or FIM, and 
has less adverse events than DTwP vaccine (1, 2). In 1998, Heininger and colleagues 
compared the Lederle/Takeda DTaP with Lederle DTwP, and found that DTaP had a 
little cross protection against B. parapertussis while the DTwP had no protection 
(26). The Massachusetts study during 2005-2009 revealed that neither the whole cell 
nor the acellular vaccine conferred protection against B. holmesii (2, 25). These 
findings highlight the need to develop vaccines specifically for B. parapertussis and 
B. holmesii. 
DTaP vaccine consists of two immunization courses, primary and booster. Three 
doses are administered at the ages of 2, 4, and 6 months in the primary 
immunization. Booster doses are administered at the age of 18 months and 4 years, 
and also recommended at 11-12 years of age and or for any adult who had not 
previously received the vaccine (3). 
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1.6 Treatment 
Whooping cough can be treated with a number of antibiotics, with oral erythromycin 
being the main antibiotic used over 30 years. Starting treatment at the early stage of 
the disease is important. Administration of the antibiotic during the initial catarrhal 
stage of the disease is more effective in eliminating the bacteria from the upper 
respiratory tract and shortening the duration of illness and the period of 
contagiousness compared with untreated patients. Initiation of antibiotics therapy 
after paroxysmal stage is not very beneficial as shown by the lack of effects on 
reducing both duration and severity of the disease; however it may reduce the risk of 
transmission (1). 
In the later stage, treatment with corticosteroids, salbutamol, pertussis specific 
immunoglobulin or antihistamines have been used to reduce severity of coughing 
with little effect. It has been shown that patients treated with antibiotics before the 
paroxysmal stage developed had fewer numbers of coughs than the untreated patients 
(29). 
 
 
 
 
 
 
 
 
 
 
 Chapter 1 Introduction 29 
1.7 Laboratory Detection 
Laboratory methods for detection of Bordetella species include bacterial culture, 
direct fluorescent antibody test, serology and polymerase chain reaction (PCR). 
Culture is the first method used to detect Bordetella species. PCR is currently the 
most popular technique used in most laboratories because of high sensitivity and 
specificity (1). 
 
1.7.1 Culture  
Bacterial culture has been the gold standard diagnostic test for B. pertussis and B. 
parapertussis. B. pertussis is a fastidious organism requiring specialised culture 
media such as Bordet-Gengou or Regan Lowe agars to grow. Unlike B. pertussis, B. 
parapertussis grows on sheep blood or chocolate agar (4). B. holmesii is a fastidious, 
slow growing bacterium which produces soluble light brown pigments on brain heart 
infusion tyrosine agar (27). Bordetella species are very sensitive to temperature and 
humidity. Therefore, the culture plates must be kept in a moist chamber or in a 
plastic bag to avoid drying and maintaining the incubation temperature at 35ᵒC is 
critical. Cultures are kept for 12 days before being discarded as negative. Colonies 
usually become detectable on 5-7 days. B. pertussis colonies are small, convex, grey, 
smooth and very shiny with no haemolysis. B. parapertussis colonies are smooth, 
opaque, and beta-haemolytic. B. holmesii colonies are similar to those of B. pertussis, 
except that they show variable beta-haemolysis (49).  Identification of bacteria is 
performed by Gram stain and several different biochemical tests. Different 
biochemical nature of each strain reveals the identity of specific Bordetella species 
(Table 1.3).  
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Table 0.3 Biochemical nature of B. pertussis, B. parapertussis and B. holmesii  
Biochemical test B. pertussis B. parapertussis B. holmesii 
Motility - - - 
Catalase + + V(W) 
Oxidase + - - 
Urease - + - 
Soluble pigments on peptone 
agar 
N/A Brown Brown 
V= Variable, W= Weak (49).    
The main disadvantages of culture as a diagnostic method are low sensitivity (Table 
1.4) and a long incubation time. Maintaining viability of the bacteria is very 
important for culturing and it is affected by factors such as patient age, vaccination 
status, specimen type and quality, transport medium and culture conditions (4). 
Nasopharyngeal aspirates and sputum are the most suitable specimen types for the 
culture (46). Culture is more specific than the other techniques; therefore, it is still 
widely used in quality assurance studies and outbreak investigations (4). 
 
1.7.2 Direct Fluorescent Antibody  
Direct fluorescent antibody (DFA) test is a rapid test used previously to detect B. 
pertussis and B. parapertussis. It contains fluorescently tagged antibodies against 
specific Bordetella antigens. These antibodies bind with the bacterial antigens and 
produce the antigen-antibody complex, which can be detected microscopically. The 
technique is low in specificity due to possible cross reactions with other bacteria in 
normal flora. DFA test may be affected by factors such as poor quality of specimens, 
transport and handling. It is more sensitive than culture and has shorter turnaround 
 Chapter 1 Introduction 31 
time. However, it has lower sensitivity compared to molecular techniques (Table 1.4) 
(1). Currently, it is not used as a routine diagnostic test in most laboratories (4). 
Table 0.4 Specificity and sensitivity of Bordetella detection methods      
Technique Specificity (%) Sensitivity (%) 
Culture 100 38 
DFA 98 52 
Serology 90 68 
End-Point PCR 97 83-100 
Real-Time PCR  97 83-100 
(44, 45) 
 
1.7.3 Serology 
Serology is used to detect the B. pertussis specific IgG or IgA in patient sera using 
the enzyme-linked immunosorbent assay (ELISA) as a diagnosis of infection. This 
test is not widely available in most diagnostic laboratories due to relatively low 
sensitivity and specificity (Table 1.4). Patients under 3 months of age may fail to 
produce measurable amount of antibodies. Furthermore, the serological results 
cannot confirm acquired immunity of the patient after the infection or vaccination. 
However, serology test has been successfully used for vaccine trials and outbreak 
investigations in adolescents and adults (1). 
 
1.7.4 Polymerase Chain Reaction  
The polymerase chain reaction (PCR) method was first invented by Kary Mullis in 
1983 (61). This is an indispensable method used in medical and biological research 
laboratories, to amplify target DNA, perform DNA sequencing, gene cloning, 
forensic DNA typing, DNA based phylogeny and the detection of hereditary diseases 
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(57). Depending on the method of detection, PCR assays can be categorised into two 
groups: end-point and real-time, although these two techniques are based on similar 
principles (59). Introduction of multiplex PCRs has been shown to be very useful in 
saving time and cost by performing multiple PCR tests on a single sample.  
1.7.4.1 Principle of PCR 
The PCR technique has the ability to amplify a single copy of DNA to thousands or 
even millions of copies, making it a highly sensitive method for detection of targets 
at low concentrations, like pathogens in clinical specimens. This method is based on 
repeated cycles of incubating sample DNA in the reaction mixture at various 
temperatures, allowing DNA melting, primer annealing and enzymatic synthesis of 
new DNA strands (61). 
1.7.4.2 PCR Components 
PCR has four key components for action: template DNA, oligonucleotide primers, 
DNA polymerase and deoxyribonucleotide triphosphates (dNTPs). Mixture of these 
components forms the reaction mixture.  
1.7.4.2.1 Template DNA 
Target DNA is used as template for amplification to produce multiple copies at 
concentration high enough for detection. The optimum amount of template DNA for 
100µl of reaction mixture is 0.1-1µg of genomic DNA. A large amount of template 
DNA increases the production of non-specific PCR products (60). RNA can also be 
used in PCR reactions by first treating it with reverse transcriptase to produce 
complementary-DNA (57). 
1.7.4.2.2 Primers 
Primers are short oligonucleotides with sequences complimentary to a designated 
region on the target gene. They usually are 18-24 nucleotides in length, with 50-60% 
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of guanine-plus-cytosine (G+C) content, and chemically synthesised. Typical final 
primer concentrations in the reaction mixture are 0.1-0.5µM. High concentrations of 
primers may form primer dimers and produce significant amount of non-specific 
products. Design of target-specific primers is crucial for a successful PCR test, which 
can be done using primer designing software. The primers should be tested for cross-
reaction against both related and unrelated DNA species (60).  
1.7.4.2.3 DNA polymerase 
DNA polymerase is an enzyme with ability to withstand high temperature (up to 
100°C) during the incubation. Taq DNA polymerase is the most commonly used 
enzyme in PCR, which is extracted from the bacterium Thermus aquaticus identified 
in hot springs. To synthesise a new DNA strand complimentary to the template 
strand, the DNA polymerase binds to the short double-stranded region formed by 
primers and the template DNA (57).   
1.7.4.2.4 Deoxyribonucleotide triphosphates  
Deoxyribonucleotide triphosphates (dNTPs) are the building blocks of new DNA 
strands, and consist of one nitrogenous base, a deoxyribose sugar and a phosphate 
group. The four dNTPs used in PCR are deoxyadenosine triphosphate (dATP), 
deoxyguanosine triphosphate (dGTP), deoxythymidine triphosphate (dTTP) and 
deoxycytidine triphosphate (dCTP). Taq DNA polymerase works by adding these 
dNTPs to the 3’-end of the newly formed DNA strand based on the sequence 
complimentary to the template DNA (57, 60).  
1.7.4.2.5 Magnesium Chloride 
MgCl2 can have a significant effect on the product formation and specificity in PCR. 
A low MgCl2 concentration in the reaction mixture can lead to a low yield of 
product. On the other hand, a high MgCl2 concentration may increase non-specific 
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products. Therefore, it is very important to optimize the MgCl2 concentration for 
individual PCR assays (60).  
1.7.4.3 Protocol of the PCR 
Figure 1.3 shows schematically the three cyclic steps in a PCR. DNA strands 
synthesised in the one cycle work as DNA templates in the next cycle. In theory, the 
amount of PCR product is doubled at the end of each cycle, and it becomes the 
dominant DNA in the reaction mixture (57).   
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Figure 0.3 Schematic diagram of the three cyclic steps in a PCR 
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A) DNA denaturation 
The two stands in the DNA double helix are held together by hydrogen bonds. By 
heating to 94-98°C, these bonds are disrupted, allowing the double DNA strands to 
dissociate into two single strands (1).  
B) Annealing  
Primers targeting a specific region of the target DNA are allowed to bind to the 
single-stranded DNA at a low temperature between 50-65°C (1). One primer is 
designed to anneal with the lag strand, while another with the log strand. Primers 
bind to the 3’-end of the template DNA, and the new DNA is synthesised towards the 
5ʹ-end (57). 
C) Elongation  
At the elongation step, DNA polymerase mediates continuous addition of dNTPs to 
the 3’-end of the newly formed DNA strands with the single-stranded DNA as 
templates.  
The three steps of PCR are usually repeated for 30-45 cycles, so that the copy 
number of target DNA would be increased exponentially for detection. This test is 
rapid and can process many samples simultaneously (14). Compared to other 
methods, PCR is the most sensitive with a high specificity, and has become a routine 
technique in most diagnostic laboratories (1).  
1.7.4.4 PCR Product Detection Methods 
A number of methods have been developed for detecting PCR products (Table 1.5). 
The most popular methods are agarose gel electrophoresis and polyacrylamide gel 
electrophoresis in diagnostic laboratories, followed by visualization of the products 
stained with fluorescent dyes (ethidium bromide or SYBR Green) under UV trans 
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illumination. Both techniques employ electrophoretic separation of DNA molecules 
based on their sizes.  
Table 0.5 PCR Product Detection Methods and Visualization 
Product Detection Method Visualization 
Agarose and/or polyacrylamide gel 
electrophoresis (ethidium bromide or 
SBYR Green staining) 
UV trans-illuminator 
Southern blotting (hybridization with 
labelled probe) 
Incorporation of label into amplifying 
sequence 
Silver staining 
Capillary Electrophoresis Image analyser 
Restriction Endonuclease Digestion Agarose or polyacrylamide gel 
Dot blots Hybridization with labelled probe 
High-Pressure Liquid Chromatography UV detection 
Electro-chemiluminescence Voltage-initiated chemical 
reaction/photon detection 
Direct Sequencing Radioactive or fluorescent-based DNA 
sequencing 
Adapted from 
http://www.cryst.bbk.ac.uk/pps97/assignments/projects/borek/Domina/page6.html 
 
1.7.4.5 Specimens  
Specimens for Bordetella PCR testing should be collected at the onset of symptoms. 
The factors such as antibiotic treatment prior to sample collection, patient age and 
duration of symptoms can affect the test sensitivity (4). The specimens need to be 
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collected with ciliated epithelial cells in the upper respiratory tract which harbour the 
bacteria (1). Nasopharyngeal aspirates (NPA) and nasopharyngeal swabs are the 
preferred specimens for Bordetella PCR. Viability of the bacteria is not important in 
this test therefore, the specimens can be sent as a dry cotton swab or in sterile saline. 
Dacron and rayon swabs are acceptable for PCR testing (4). 
1.7.4.6 PCR targets  
A number of targets on the bacterial genomes have been used for detection of 
different Bordetella species (Table 1.6). Single copy targets such as pertussis toxin 
promoter (ptxP), adenylate cyclase and pertactin are more specific to the species but 
lower in sensitivity. Multicopy targets such as the insertion sequences IS481, IS1001 
and IS1002 are more sensitive but lack specificity due to their occurrence among 
multiple Bordetella species (4). 
IS481 is the most common target for B. pertussis PCR, which is present at 50 – 238 
copies per genome. However, it has also been found in the B. holmesii and B. 
bronchiseptica genomes (4).Up to 22 copies of IS1001 specific for B. parapertussis 
(pIS1001) have been found in the bacterial genome (41). B. holmesii has an IS1001-
like sequence (hIS1001), which is present at 8-10 copies per genome (27).      
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Table 0.6 PCR Targets for different species of Bordetella. 
Bordetella 
species 
IS481 pIS1001 ptxP IS1002 hIS1001 BP485 BP283 Fla 
gene 
B. pertussis √ × √ √ × √ √ × 
B. 
parapertussis 
× √ × √ × × × × 
B. holmesii √ × × × √ × × × 
B. 
bronchiseptica 
√ √ × √ × × × √ 
 
BP485: B. pertussis 485; BP283: B. pertussis 283; pIS1001: B. parapertussis specific 
IS1001; hIS1001: B. holmesii specific IS1001; ptxP: pertussis toxin promoter  
(1, 6, 9, 11, 15, 27). 
 
1.8 Research Plan 
B. parapertussis and B. holmesii are increasingly recognised in the Bordetella family 
as causes of whooping cough like disease. A few studies outside Australia have 
previously shown that infection with B. parapertussis and B. holmesii occurred in 
various geographical locations at different incidence rates. In a four-year study 
(2007-2011) in Tunisia, the incidence of B. pertussis and B. parapertussis infection 
was shown to be 82% and 6% respectively. The laboratory detection was done using 
the target IS481 for B. pertussis, pIS1001 for B. parapertussis, combined with ptxP 
specific for B. pertussis and recA gene specific for B. holmesii (9). In a study on 
clinical specimens collected from 9 states in the US during 2008-2010, an incidence 
of 39% and 14% was detected for B. pertussis and B. parapertussis infection, 
respectively. IS481 and IS1001 were used as PCR targets for B. pertussis and B. 
parapertussis, respectively, in this study (50). 
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B. holmesii is the most recently recognised member of the Bordetella family that 
causes whooping cough illness. A study in Ohio (2010-2011) found that a significant 
portion of the outbreak of whooping cough like-illness was caused by B. holmesii, 
with 68% and 29% of the specimens being positive for B. pertussis and B. holmesii, 
respectively. Targets used in this study were IS481 for B. pertussis and B. holmesii, 
pIS1001 for B. parapertussis with ptxP for B. pertussis and hIS1001 for B. holmesii 
to differentiate these species (16). In an outbreak of whooping cough illness in Japan 
during 2010-2011, it was reported that 29 and 6 out of 35 cases were infected with B. 
pertussis and B. holmesii, respectively (20).  In a French study, 20% of samples 
collected from adults and adolescents were positive for B. holmesii DNA, and none 
with B. pertussis DNA (17). 
In Australia, B. pertussis infection is routinely tested for in most diagnostic 
laboratories. Little is known about the incidence of infection of B. parapertussis and 
B. holmesii. In our survey, there is no previous report on the contribution of B. 
parapertussis and B. holmesii to the overall whooping cough incidence in Australian 
children. To address this question, the present project aims: 
1. To develop specific and sensitive PCR tests for B parapertussis and  
B. holmesii  
2. To investigate the incidence of infection of B. parapertussis and B. holmesii 
compared to that of B. pertussis in patients of The Children’s Hospital at 
Westmead. 
PCR assays for B. parapertussis and B. holmesii were developed and combined with 
the existing in-house PCR test for B. pertussis to develop a triple target, multiplex 
assay. The insertion sequences IS481, pIS1001 and hIS1001 were used as targets for 
B. pertussis, B. parapertussis and B. holmesii, respectively. An inhibitor control for 
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each target was synthesised and included in the multiplex PCR assay to detect false 
negative results. Investigation of the incidence of infection of B. pertussis, B. 
parapertussis and B. holmesii was done using the multiplex PCR assay. Clinical 
samples including nasopharyngeal aspirates, nasopharyngeal swabs, bronchoalveolar 
lavage and sputum from suspected patients were collected from January 2013 to 
December 2013. PCR results and in-house bacterial culture results were compared 
when available. To our knowledge, this is the first study to systematically compare 
the infection incidence of B. pertussis, B. parapertussis and B. holmesii in Australian 
children. 
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                      Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 Introduction 
All the material used in this research project is listed below in Table 2.1.  
Table 0.1 Item Description and Supplier 
Procedure Item Description Supplier 
DNA Extraction 
From Bacterial 
Cultures 
PBS (Phosphate Buffered Saline) Roche 
Diagnostics  
Australia 
MagNA Pure Bacterial Lysis Buffer Roche 
Diagnostics 
Australia 
Proteinase K Roche 
Diagnostics 
Australia 
DNA Extraction MagNA Pure Compact Nucleic Acid Isolation Kit I Roche 
Diagnostics 
Australia 
MagNA Pure LC Total Nucleic Acid Isolation Kit Roche 
Diagnostics 
Australia  
0.45% Sterile Saline BioMerieux 
Australia 
Polymerase 
Chain Reaction 
Primers Sigma-
Aldrich 
Australia 
FastStart PCR Master 50 ml Roche 
Diagnostics 
Australia  
T100TM Thermal Cycler  Bio-Rad 
Australia 
Detection by 
Capillary 
Electrophoresis   
QIAxcel DNA screening kit Qiagen 
Australia 
QX alignment marker, 15bp/1kb, 1.5ml Qiagen 
Australia 
QX Size Marker 50 - 800 bp v2.0 (50 µl) Qiagen 
Australia 
Detection by  
Gel 
Electrophoresis  
SYBR Safe DNA gel stain, 10000X concentrate, 
400ml/pack 
Life 
Technologie
s Australia 
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100bp DNA ladder, 50mg, 1mg/ml Life 
Technologie
s Australia 
Agarose LE, Analytical Grade, 500g/pack Promega 
Australia 
Blue/Orange 6X Loading Dye Promega 
Australia 
TBE (Tris Borate and EDTA) Buffer Promega 
Australia 
PCR Product 
Purification  
Using Vacuum 
Manifold    
Wizard PCR Preps DNA Purification System Promega 
Australia 
Nuclease Free Water Seegene 
Australia 
80% Isopropanol BioMerieux 
Australia 
DNA 
Purification for 
Sequencing 
Exonuclease 1 Epicentre, 
Madison, 
USA 
Rapid Alkaline Phosphate Roche 
Diagnostics 
Australia 
Culture Charcoal Agar BioMerieux 
Australia 
Horse Blood Agar BioMerieux 
Australia 
Brain-Heart Infusion Broth BioMerieux 
Australia 
Tyrosine Soy Broth …….. 
B. pertussis Anti-serum Remel-
Oxoid 
Australia 
B. parapertussis Anti-serum Remel-
Oxoid 
Australia 
 
2.1.2   Materials Used in DNA Purification in Bacterial Cell Culture 
2.1.2.1 Phosphate Buffered Saline  
Phosphate Buffer Saline (PBS) was used as a medium to dispense the bacterial 
colonies. It contains sodium phosphate and sodium chloride. Preparation was done in 
the laboratory by reconstituting dry PBS power in sterile de-ionized water and stored 
at room temperature. Small aliquots were used as per need, to avoid contaminations.  
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2.1.2.2 MagNA Pure Bacterial Lysis Buffer 
MagNA Pure Bacterial Lysis Buffer is intended for general laboratory use. It was 
stored at room temperature. Buffer was used before the expiration date printed on the 
label due to its instability. 
2.1.2.3 Proteinase K 
 Proteinase K was stored at 4⁰C. Small aliquots were prepared from the original by 
adding double distilled water or Tris buffer and stored at -20⁰C. The aliquots are 
stable for up to 1 year if they are stored properly. Repeated freezing and thawing can 
lead to protein precipitation.  
 
2.1.3 Materials Used in DNA Extraction 
2.1.3.1 0.45% Sterile Saline 
0.45% ready-to-use saline was used in sample preparation before the nucleic acid 
extraction. Saline was aliquoted daily in to small containers, to minimise 
contaminations and stored at room temperature.  
2.1.3.2 MagNA Pure Compact Nucleic Acid Isolation Kit I 
MagNA Pure Compact Nucleic Acid Isolation kit I contains, ready-to-use reagent 
cartridges, disposable tip trays, sample tubes, barcoded elusion tubes and elusion 
tube caps. This kit was used to extract total nucleic acid in up to 400µL of respiratory 
specimens at CHW. It can process 8 samples in one run. 
2.1.3.3 MagNA Pure LC Total Nucleic Acid Isolation Kit 
MagNA Pure LC Total Nucleic Acid Isolation Kit contains, wash buffer I, wash 
buffer II, wash buffer III, lysis/binding buffer, proteinase K (in 6 glass vials with 
lyophilizate), magnetic glass particles (6 glass vials), elusion buffer. This kit was 
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used to isolate total nucleic acid in 200µL of respiratory specimens at CHW. It can 
process 32 samples in one run.  
 
2.1.4 Materials used in PCR 
2.1.4.1 PCR Primers 
The oligonucleotide primers used in detection of B. pertussis, B. parapertussis and B. 
holmessi and their inhibitor controls are listed in Table 2.2. 10µM primer stock was 
prepared from 200µM original stock for each primer set. Primers were stored at -
20⁰C with the tube labelled with the primer name, concentration and the date of 
preparation.  
 
Table 0.2 Primers Used in Monoplex and Multiplex PCR Assay  
P
CR 
rimer Sequence 5ʹ-3ʹ Amplicon 
Size (BP) 
Ref 
B
BP 
PCR 
BP-1 GATTCAATAGGTTGTATGCATGGTT 153 
Taken from 
Existing 
in-house PCR 
BP-4 AATTGCTGGACCATTTCGAGTCGACG 
BP-5 AATGCGCAAGCCTGATGTCAGTCATGAGTGAACTGGGGGG 
185 
BP-6 ATCAGGCTTGCGCATTGCTAGCTAAGGAGCCCGGCCGGAT 
B
BPP 
PCR 
PPF GGCCAAGTATGGACGAGAGG 
226 In-house 
PPR CCAGAGCCGTTTGAGTTCGT 62 
BPP1 AATGCGCAAGCCTGATGTCAGTCACGCAGCAGCAGCCAGC 258 
In-house 
BPP2 ATCAGGCTTGCGCATTGCTAGCTACAACCGTGACAACCTG In-house 
B
BH 
PCR 
BHF CGACAGCGAGACAGAATCCC 
341 68 
BHR ATAGACCGGGTGCGTGTAGA In-house  
BH1 AATGCGCAAGCCTGATGTCAGTCAGTCATATCTGATGCGCGATG 381 
In-house 
BH2 ATCAGGCTTGCGCATTGCTAGCTAGCTAAGCGGTGAGCAAGGGC In-house 
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2.1.4.1.1 Bordetella pertussis primer selection 
B. pertussis monoplex PCR assay was the existing assay at CHW. The primer pair 
for B. pertussis was designed and inhibitor control was synthesised at The 
Department of Molecular Pathology. 
 
In-house Forward Primer: GATTCAATAGGTTGTATGCATGGTT 
Query  34535  GATTCAATAGGTTGTATGCATGGTT  34559 
                          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  
BP1                 GATTCAATAGGTTGTATGCATGGTT  25 
 
Reverse Primer: AATTGCTGGACCATTTCGAGTCGACG 
Query  28172  AATTGCTGGACCATTTCGAGTCGACG  28197 
                           |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   
BP4                 AATTGCTGGACCATTTCGAGTCGACG  26 
 
2.1.4.1.2 Bordetella parapertussis primer selection  
B. parapertussis PCR assay was a newly developed assay, which was combined with 
the B. pertussis PCR assay to develop the multiplex PCR assay. Alignment of both 
forward (PPF) and reverse (PPR) primer with B. parapertussis genome is shown 
below. 
In-house Forward Primer: GGCCAAGTATGGACGAGAGG 
 
 
Query  805  GGCCAAGTATGGACGAGAGG  824 
                       |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
PPF             GGCCAAGTATGGACGAGAGG  20 
  
 
Reverse Primer: CCAGAGCCGTTTGAGTTCGT 
 
Query  1011  ACGAACTCAAACGGCTCTGG  1030 
                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
PPR               ACGAACTCAAACGGCTCTGG  1 
 Chapter 2 Materials and methods 46 
2.1.4.1.3 Bordetella holmesii primer selection 
B. holmesii monoplex PCR assay was developed second and combined with the 
multiplex B. pertussis /B. parapertussis PCR assay. Alignment of the forward (BHF) 
and reverse (BHR) primers in the B. holmesii genome is shown below. 
Forward primer: CGACAGCGAGACAGAATCCC 
Query  64  CGACAGCGAGACAGAATCCC  83 
                   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
BHF          CGACAGCGAGACAGAATCCC  20 
 
In-house Reverse Primer: ATAGACCGGGTGCGTGTAGA 
Query  385  TCTACACGCACCCGGTCTAT  404 
                     |  |  |  |  |  |  |  |  | |  |  |  |  |  |  | |  |  |  | 
Sbjct  20     TCTACACGCACCCGGTCTAT  1 
 
2.1.4.2 Faststart PCR Master Mix 50mL 
Faststart PCR Master was a ready-to-use, 2X concentrated master mix contains, 
Faststart Taq DNA polymerase, magnesium chloride, double concentrated reaction 
buffer and nucleotides. It was stored between -15⁰C to -25⁰C.  
2.1.4.3 Samples 
No DNA control (NDC), no sample control (NSC), patient samples (S1, S2), 
extraction positive control (EPC), and positive control (PC) were included in every 
PCR assay.  
2.1.4.4 Bio-Rad 100TM Thermal Cycler 
Bio-Rad 100TM Thermal Cycler is robust and economical for routine PCR. It contains 
block of 96 wells to run the samples and a graphical touch screen as the user 
interface.  
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2.1.5 Materials used in DNA Detection by Capillary Electrophoresis  
2.1.5.1 QIAxcel DNA Detection Kit 
QIAxcel DNA screening kit contains ready-to-used gel cartridges, separation buffer, 
wash buffer, mineral oil, DNA dilution buffer and 12, 0.2 mL tube strips. This is a 
fully automated, sensitive, capillary electrophoresis system that can run up to 96 
samples for DNA detection.   
2.1.5.2 QX Alignment Marker, 15bp/1kb, 1.5ml 
Use correct alignment markers are very important in determination of optimal size of 
the DNA fragments. It was changed every 15-20 runs or as per need for better results 
and was stored at -20⁰C between uses.  
2.1.5.3 QX DNA Size Marker 50 - 800 bp v2.0 (50 µl) 
QX DNA Size Marker was used as a reference marker to compare all the peaks to 
determine the product size. Using a size marker close to the DNA fragment size of 
the sample will help to obtain more accurate results. Creating a reference DNA 
marker table allows determination of the product size without the need to run a QX 
DNA size marker in each run. Creation of a new size DNA marker table for every 8 
runs of after each 96-well plate is recommended.  
 
2.1.6 Materials Used in DNA Detection by Gel Electrophoresis 
2.1.6.1 SYBR Safe DNA Gel Stain, 10000X Concentrate, 400mL/pack 
SYBR Safe DNA gel stain is a high sensitive stain used in visualisation of DNA in 
agarose gel under UV excitation at CHW. It was stored in the dark to protect against 
light degradation at room temperature.  
 Chapter 2 Materials and methods 48 
 
2.1.6.2 100bp DNA Ladder, 50mg, 1mg/ml 
100bp DNA ladder ranging from 100 to 1500bp was used for sizing of double 
stranded DNA (refer figure 2.1). The DNA ladder was visualised on 1-2% SYBR 
safe stained agarose gel. It was stored at -20⁰C. 
 
  
Figure 0.1 100bp DNA Ladder  
 
2.1.6.3 Agarose LE, Analytical Grade, 500g/pack 
Agarose LE, Analytical Grade was used to separate the nucleic acids by 
electrophoresis. It was stored at room temperature.  
2.1.6.4 Blue/Orange 6X Loading Dye 
Blue/Orange 6X Loading Dye, a ready-to–use dye, was mixed with the sample 
before loading it into the gel electrophoresis wells. This helped in tracking migration 
of the sample during the electrophoresis. It was stored at -20⁰C. 
2.1.6.5 TBE Buffer 
TBE (Tris borate and ethylene di-amine tetra acetic acid (EDTA)) buffer is intended 
to use in electrophoresis of nucleic acid in agarose and polyacrylamide gels. TBE 
 Chapter 2 Materials and methods 49 
was used as a running buffer and also as a gel preparation buffer at CHW. It was 
stored at room temperature.  
 
2.1.7 Materials used in PCR Product Purification Using Vacuum Manifold 
2.1.7.1 Wizard PCR Preps DNA Purification System 
This system is a simple and quick way of purifying PCR amplified double standard 
DNA. The system includes; Wizard® PCR prep DNA purification resin, direct 
purification buffer, Wizard mini-columns and syringe barrels.  
2.1.7.2 80% Isopropanol 
80% Isopropanol was used to precipitate DNA in the resin/DNA mixture, on to the 
mini-column.   It was made by reconstituting 100% Isopropanol in water (8:2) and 
stored in a glass container at room temperature, on a laboratory shelf.   
2.1.7.3 Nuclease Free Water 
Nuclease free water is pure quality tested water suitable for laboratory use. This was 
stored at room temperature. These were prepared as small 1mL aliquots to minimise 
contaminations during the experiments.   
 
2.1.8 Materials Used in DNA Purification for Sequencing 
2.1.8.1 Exonuclease 1  
Exonuclease 1 was used to purify the PCR product prior to sequencing by removing 
leftover primers. It was stored at -20⁰C. 
2.1.8.2 Rapid Alkaline Phosphate 
Rapid alkaline phosphate was used to purify the PCR product by removing excess 
dNTPs. This was stored at -20⁰C. 
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2.1.9 Materials used in Bordetella Culture 
2.1.9.1 Charcoal Agar 
Charcoal agar was the selective bacterial growth medium used to culture Bordetella 
species at CHW. The media was specially design to culture B. pertussis and B. 
parapertussis. Plates were stored at 4⁰C and used before the expiration date printed 
on the plate. 
2.1.9.2 Horse Blood Agar 
Horse Blood Agar (HBA) was used to culture known positive controls samples of all 
three species of Bordetella during assay development. The media was enriched with 
horse blood to isolate fastidious microorganisms like B. parapertussis which exhibit 
beta haemolysis on HBA. Plates were stored at 4⁰C.        
2.1.9.3 Brain Heart Infusion Broth 
Brain Heart Infusion Broth (BHIB) is a highly nutritious general purpose culture 
medium used at CHW. Ready-to-use BHIBs were stored at 4⁰C. Serial dilutions of 
Bordetella positive controls were done using this broth to ensure the viability of 
bacteria.  
2.1.9.4 Tryptic Soy Broth 
Tryptic Soy Broth (TSB) was used in serial dilution experiments in this study. It was 
made by reconstituting dry TSB power in sterile de-ionized water. The TSB was 
autoclaved at 121⁰C for 15 minutes and poured into small aliquots. Broth was stored 
in the dark at room temperature. 
2.1.9.5. B. pertussis Identification 
B. pertussis antisera consist of antibodies to B. pertussis antigens. This was used in 
serological identification of B. pertussis culture by slide agglutination test at CHW. 
Antisera were stored at 4⁰C.  
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2.1.9.6 B. parapertussis Identification 
B. parapertussis antisera consist of antibodies to B. parapertussis. It was used in 
serological identification of B. parapertussis culture by slide agglutination test. 
Antiserum was stored at 4⁰C. 
2.1.9.7 B. holmesii Identification  
B. holmesii was identified using a technique called MALDI-TOF (Matric-Assisted 
Laser Desorption/Ionisation – Time of Flight) Mass Spectroscopy, using fresh B. 
holmesii colonies grown on charcoal agar plates. 
 
2.2 Methods 
2.2.1 Introduction 
Respiratory specimens received in the Department of Microbiology and Infectious 
Disease at CHW from 2012 September to 2013 December, from children with 
persisting respiratory symptoms, were used in this study. Specimens included 
nasopharyngeal aspirate (NPA), nasopharyngeal throat swabs, broncho-alveolar 
lavages (BAL) and endotrachealaspirates (ETA).  DNA was extracted from the 
respiratory specimens and was stored in -20⁰C until tested using the Bordetella 
multiplex PCR. Amplification of the DNA was performed by conventional end-point 
PCR and the products were detected using capillary electrophoresis or agarose gel 
electrophoresis. All the positive and negative samples were stored separately 
according to their accession numbers.  Simultaneously, a Bordetella culture was 
performed by laboratory staff at the Department of Microbiology. We have used the 
“culture” as the gold standard in our study to determine sensitivity and specificity of 
the multiplex PCR.    
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2.2.2 DNA Extraction from Bacterial Colonies 
Bordetella colonies were picked up from fresh 2-3 days old culture and suspended in 
200µl of phosphate buffer saline (PBS). 180µl of MagNA Pure bacterial lysis buffer 
and 20µl proteinase K were added into the suspension to digest the cell wall and 
proteins respectively. The cell suspension was then vortexed vigorously to prepare a 
homogenous mixture, and incubated at 65⁰C for 10 minutes. The lysate was 
centrifuged briefly to bring all the droplets down and transferred into a sample tube 
for DNA extraction. The DNA was extracted using the bacterial DNA extracting 
protocol in the MagNA Pure compact kit I. 
 
2.2.3 DNA Extraction from Respiratory Specimens 
2.2.3.1 DNA Extraction by MagNA Pure Compact   
The specimens were prepared in 0.45% sterile saline and dispensed into sample tubes 
prior to extraction with the MagNA Pure compact. 400µl of sample volume, 50µl of 
elution volume and the protocol “Total_NA_Plasma_100_400” were used in the 
extraction. Reagent cartridges, tip trays, elution tubes and sample tubes along with 
the positive and negative controls were loaded into the machine.   
DNA extraction in 7 steps as shown in figure 2.2: 
1) Sample material was placed in a sample tube. 
2) Cell destruction and protein digestion by the addition of lysis buffer and 
proteinase K. 
3) DNA binds to the magnetic glass particles (MGPs). 
4) Magnetic separation of the DNA-glass particles complex. 
5) Removal of cell debris by extensive washing steps. 
6)  Magnetic separation of the DNA-glass particle complex. 
7) Nucleic acid elution at high temperature during the removal of Magnetic 
Glass Particles. 
8) The purified DNA was eluted from the MPGs in the wells of the elusion 
cartridge 
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Figure 0.2 DNA Extraction Protocol in MagNA Pure Compact Instrument (MagNA Pure Compact 
system 2.0, Manual, Roche) 
 
2.2.3.2 DNA Extraction from the Respiratory Specimens using MagNA Pure 
Compact LC 
Samples were prepared using 0.45% saline and dispensed into sample cartridge. 
Sample volume was set for 200µl, elution volume for 50µl and extraction protocol 
was set for the extraction. The machine was loaded with the sample cartridge 
including positive and negative control samples, reagent trays, large reaction tips, tip 
stands, processing cartridges and elution cartridge. Presence of drop catcher and 
waste bag was checked before the procedure was started.  
DNA extraction in 8 steps as shown in figure 2.3: 
1) The sample material is placed into the well of sample cartridge. 
2) Lysis/binding buffer is added into the sample, resulting in complete cell lyisis 
and release of nucleic acids. 
3) Proteinase K is added to the sample and proteins are digested. 
4) DNA binds to the silica surface of the added Magnetic Glass Particles 
(MPGs). 
5) MPGs with bound DNA are magnetically separated from residual lysed 
sample. 
6) MPGs with bound DNA are washed repeatedly with wash buffer to remove 
unbound substances.  
7) MPGs with bound DNA are magnetically separated from the wash buffer 
containing residual sample debris. 
8) The purified DNA was eluted from the MPGs in the wells of the elusion 
cartridge.   
  
 
    1                      2                    3               4                5                6                7  
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Figure 0.3 DNA extraction protocol with MagNA Pure Compact LC System (MagNA Pure Compact 
DNA Isolation Kit 1, version 17.0, Manual, Roche).    
 
2.2.4 DNA Amplification  
Conventional end-point PCR was performed using a Bio-Rad 100TM thermal cycler. 
The PCR protocol was programed into the machine as mentioned in table 3.2.6. The 
PCR reaction mixture was prepared and dispensed into small reaction tube racks 
along with the samples, and the content mixed well by tapping. The lids of the 
reaction tubes were sealed properly to prevent the samples from evaporating during 
the amplification process.  The tubes were then inserted into the machine, and the 
appropriate thermo-cycling programme was selected.  Turn over time for 
amplification process of the Bordetella multiplex PCR was two hours and twenty six 
minutes.  
 
2.2.5 PCR Product Detection 
PCR product detection was done by using traditional gel electrophoresis during the 
stage of PCR assay development. 1.5% agarose gel was used for analytical purpose 
and 2% gel for inhibitor control synthesis.  Agarose gel was stained with SYBR Safe 
DNA gel stain and poured in to an appropriately sized mould with a suitable comb. 
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The samples, mixed with blue/orange 6X loading dye, were then added into the wells 
on the gel. 100 bp DNA ladder was added alongside the samples and, they were 
electrophoresed for 25minutes at 100V. Separated products on the gel were 
visualized using UV trans-illuminator. 
Sample detection was done by capillary electrophoresis using QIAxcel DNA 
screening kit. 96 samples can be tested in one run on an 8×12 platform. Processing 
time for one run (12 samples) was 8 minutes. The instrument consisted of a cartridge 
of 12 capillary tubes filled with gel to run the samples. QX DNA alignment marker 
was thawed and loaded into the machine, and samples were loaded according to their 
accession numbers. The instrument was connected to a computer with the QX DNA 
screening software. Sample information was then entered into the instrument prior to 
commencing run. Results were displayed on the computer screen in the format of a 
gel image and electropherogram.   
 
2.2.6. PCR Product Purification Using Vacuum Manifold 
2.2.6.1 PCR Product Preparation   
Wizard® PCR preps DNA purification system was used to purify the synthesised 
inhibitor control. The DNA band was excised from the gel immediately and 
transferred into a 1.5ml microcentrifuge tube. 1ml of resin was added and incubated 
at 65⁰C for 5 minutes until the agarose was melted.  
2.2.6.2 PCR Product Purification 
Wizard® mini-columns were prepared for each sample and the syringe barrels were 
attached to each mini-column. This mini-column / syringe barrel complex was then 
attached to the vacuum manifold. The resin/DNA mix was added into the syringe 
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barrel and the vacuum applied to the liquid through the mini-column. The vacuum 
was released after all the liquid passed through the mini-column. 
2.2.6.3. Washing 
2mL of 80% Isopropanol was added to the syringe barrel and the vacuum applied to 
pull the isopropanol through the mini-column. The resin was dried by applying 
additional vacuum for 30 seconds. The syringe barrel was removed and the mini-
column was transferred into a 1.5mL micro-centrifuge tube for centrifugation at 
10,000 x ɡ for 2 minutes. 
2.2.6.4 Elution 
The mini-column was transferred into a clean 1.5mL micro-centrifuge. 50µl of 
nuclease free water was added and held for 1 minute before the tube was centrifuged 
at 10,000 x ɡ for 20 seconds at room temperature. The mini-column was discarded 
and the DNA was stored at -20⁰C.  
 
2.2.7 DNA Purification for Sequencing 
DNA purification was done on all three species of Bordetella used in this study for 
sequencing. PCR product was pre-treated with a combination of Exonuclease I and 
Shrimp Alkaline Phosphate according to following ratio:    
Amplified PCR Product       10.0 µl 
Exonuclease I                       0.5 µl 
Shrimp Alkaline phosphate    1.0 µl 
Total                                  11.5 µl 
Exonuclease I was used in removing residual primers and single stranded DNA. 
Shrimp Alkaline Phosphate was involved in removing excess dNTPs from the PCR 
mixture. The PCR mixture was incubated at 37⁰C for 30 minutes allowing the 
enzymatic reactions to take place. The enzymatic reactions were inactivated by 
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heating the mixture to 85⁰C for 15 minutes. The purified products were sent to 
ICPMR at Westmead for sequencing and viewed using the BioEdit programme in 
section 3.2.6.2 for B. parapertussis and section 3.3.6.2 for B, holmesii. 
 
2.2.8 Culture 
2.2.5.1 Culture Inoculation 
Freshly collected specimens including nasopharyngeal aspirates and bronchial 
alveolar lavages were immediately transported to the laboratory for culturing. 
Specimens were inoculated onto charcoal agar plates by firmly rolling a swab over 
one third of agar surface and streaking into four quadrants to minimize overcrowding 
by break-through microorganisms which can suppress the growth of Bordetella. The 
plate inoculation process was done in a level two biohazard cabinet. The plates were 
labelled with the accession number and the inoculation date before incubation. A 
positive control plate was included in every batch of samples.  
2.2.8.2 Incubation 
Plates were placed in a moistened aerobic jar to avoid drying during the incubation. 
Filter papers, soaked with sterile distilled water, were layered at the bottom of the jar 
to moisten the interior environment. Plates were place in an aerobic atmosphere with 
less than 5% CO2.   Incubation was done at 35⁰C for 5 to 12 days. Maintaining 
incubation temperature at 35⁰C was very crucial for the growth of B. pertussis as it 
does not support the growth at 37⁰C.  Bordetella colonies were detected within 5-
7days. However, it can take up to 12 days for maximum recovery.  If no colony 
formation occurred by the 12th day, the cultures were declared negative and 
discarded. 
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2.2.8.3 Culture Examination 
Plates were visualised daily by a laboratory technician to check the progress of 
colony formation. B. pertussis colonies started appearing from day 2. They were 
small, convex, gray, smooth, and very shiny like mercury drops. The appearance of 
B. holmesii colonies was very similar to B. pertussis colonies on charcoal agar. B. 
parapertussis colonies were larger and duller than B. pertussis colonies. B. holmesii 
did not demonstrate a heavy growth on charcoal agar, and the incubation time was 
longer than for B. pertussis or B. parapertussis.  
Serological agglutination testing was performed on suspected colonies of B. pertussis 
and B. parapertussis. A drop of saline was added onto a clean slide and few bacterial 
colonies were suspended in it. Ready-to use B. pertussis or B. parapertussis 
antiserums were added onto the slides and examined under 30X magnification for 
agglutination. A control slide consists of saline and bacterial colony suspension, and 
the antiserum slides for each species were performed separately at the same time. A 
4+ rapid reaction with large clumps and clear background was considered as a 
positive result, if the negative control was negative. Additional tests were not 
required except for an equivocal result. 
 MALDI-TOF Mass Spectroscopy was used to detect B. holmesii.  Freshly grown B. 
holmesii colonies were uniformly mixed with a suitable matrix material and applied 
to a metal surface. The sample-matrix material was irradiated and vaporised by a 
laser. These ionised molecules were then guided into the flight tube, which separated 
them according to their mass. The results were generated by the detector according to 
their time of flight (TOF) through the flight tube. This technique has been proven to 
be very specific for bacterial identification (67).  
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Chapter 3 Development and validation of PCR assays 
3.1 Introduction 
This chapter explains the development of Bordetella multiplex PCR assay. The aims 
of this study were to develop reliable and sensitive and specific laboratory diagnostic 
tool to detect three Bordetella species, B. pertussis, B parapertussis and B. holmesii, 
and to investigate the incidence of infection with these three species at CHW. The B. 
parapertussis and B. holmesii monoplex PCR assays were firstly developed and 
validated, followed by the development of Bordetella multiplex PCR assay for B. 
pertussis, B. parapertussis and B. holmesii. Designing of the PCR assays, 
construction of the inhibitor controls and analysis of the sensitivity and specificity, 
are explained in this chapter. Development of the Bordetella multiplex PCR assay 
was done from September 2012 to October 2012 and the validation was completed 
by January 2013.   
 
3.1.1 Bordetella Pertussis PCR Assay  
The Bordetella pertussis monoplex PCR assay was the in-house method used in the 
Department of Molecular Pathology at CHW, to detect B. pertussis infection. This 
was a routine test conducted by CHW laboratory staff. All the specimens with a 
request for B. pertussis screening were tested using this PCR assay. All initial 
preparation of the specimen, assay performance and reporting of the results, was 
done by the laboratory staff.  
The size of the forward primer (BP1) for B. pertussis target DNA was 25nt and the 
reverse primer (BP4) was 26nt. This primer pair encodes a product of 153bp. Both 
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forward (BP5) and reverse (BP6) primers for B. pertussis inhibitor control are 40nt 
and encode a product of 185bp.  
 
3.1.2 Preparation of the Reaction Mixture and PCR 
Constituents in the reaction mixture for the B. pertussis PCR assay are shown in table 
3.1. The forward and reverse primers for B. pertussis PCR were stored at -20⁰C in 
the pre PCR area. These tubes were thawed immediately before the preparation of 
the reaction mixture. 15µl of the mixture was added to each tube and transported to 
PCR preparation area for further processing.  The final primer concentration of the 
reaction mixture was 0.3µM. 
  Table 0.1 Reaction mixture for B. pertussis PCR 
Constituents µl per 
Sample 
FastStart Master Mix 12.50 
Forward primer, BP1 (10µΜ) 0.63 
Reverse primer, BP4 (10µΜ) 0.63 
H2O 1.24 
Total 15.00 
 
The PCR preparation area was divided into two sections. The no DNA control 
(NDC), the no sample control (NSC) and the patient samples were added into the 
appropriate PCR tubes in section one of the PCR area. The positive control (PC), the 
extraction positive control (EPC) and the inhibitor control were added in the second 
section of the PCR area, to prevent cross-contamination. Tubes were sealed and 
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mixed well. PCR amplification was performed and products were detected using 
QIAxcel capillary gel electrophoresis.  
 
3.1.3 Specificity of the B. pertussis PCR 
3.1.3.1 Testing the B. pertussis PCR test against B. parapertussis and B. 
holmesii 
The B. pertussis PCR target was the IS481 region of the B. pertussis genome, which 
is present as 50-238 copies per genome (63). The assay was very sensitive due to the 
high copy number of the target sequence. However, B. holmesii also shares the same 
target sequence (IS481) with 8-10 copies per genome (63). Therefore, this assay had 
poor specificity. The B. pertussis PCR assay was performed to determine the 
specificity, is shown in figure 3.1.  
 
Figure 0.1 Specificity of the B. pertussis PCR assay, compared with the B. parapertussis and B. 
holmesii 
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BP - B. pertussis, BPP- B. parapertussis, BH- B. holmesii, PC- positive control, and 
IC- inhibitor control 
The results show that, B. holmesii samples produced the same size band as B. 
pertussis. This assay detects both B. holmesii and B. pertussis.   
 
3.2 Development of the B. parapertussis PCR Assay 
3.2.1 Primer designing  
 The Bordetella parapertussis monoplex PCR assay was developed using a published 
reverse primer and a forward primer designed in-house. These primers were designed 
using the primer-BLAST programme provided by the National Center for 
Biotechnology Information (NCBI). The assay targeted the B. parapertussis specific 
pIS1001 region which is present as 20-21 copies per genome (46).  The forward and 
reverse primer match for B. parapertussis is shown in table 3.2.  
Table 0.2 Forward and Reverse Primer Match 
 
Primer Sequenc
e (5ʹ-3ʹ) 
Templat
e 
strand 
Length Start Stop Tm GC% Self 
Compl- 
emen- 
tarity 
Sesf 3ʹ 
Compl- 
emen- 
tarity 
Forward 
(PPF) 
GGCCA
AGTAT
GGACG
AGAGG 
Plus 20 805 824 59.89 60.00 4.00 0.00 
Reverse 
(PPR) 
CCAGA
GCCGT
TTGAG
TTCGT 
Minus 20 1030 1011 60.60 55.00 2.00 0.00 
Product 
Length 
      226 
 
 
This primer pair was designed to generate a product of 226bp, which was 73bp 
longer than the product size of the B. pertussis (153bp), for easy separation and clear 
visualisation on the gel.    
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3.2.2 Preparation of the Reaction Mix 
The reaction mixture consisted of FastStart master mix, forward and reverses 
primers. The primers were mixed with the master mix in the pre PCR area.  The 
above ingredients were mixed in a 1.5µL eppendorf tube according to the ratio 
shown in table 3.3. The concentration of the primer stocks was 10µΜ.  
 Table 0.3 Content of the Reaction Mixture  
Ingredient µl/Samp
le 
FastStart Master Mix 12.50 µl 
Forward primer (PPF) 
  0.75 µl 
Revers primer (PPR) 
  0.75 µl 
Total 14.00 µl 
 
The final primer concentration in the reaction mixture was 0.3µM. The magnesium 
chloride (MgCl2) concentration was set at 0.5µM. The reaction mixture was pipetted 
into labelled PCR tubes immediately after mixing, and the tubes were taken to the 
PCR area for further processing. In this area, no DNA control (NDC), no sample 
control (NSC), samples (S1, S2…), extraction positive control (EPC), and positive 
control (PC) were added into appropriate tubes. Care was taken when adding PC and 
EPC, to avoid possible contamination. The tube racks were sealed and transferred to 
the post PCR area for amplification and product determination.  14µl of reaction 
mixture and 11µl of NDC/NSC/ samples / PC/ EPC were added as presented below 
in table 3.4. With addition of the samples, the total reaction mixture was 25µl.  
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Table 0.4 Content of the PCR Tubes 
Sample 
No 
Sample 
ID 
Reaction 
Mixture 
(µl) 
Sample 
Volume 
(µl) 
NCS 
(µl) 
 
EPC  
(µl) 
PC  
(µl) 
H2O 
(µl) 
Total 
Volume  
(µl) 
1 NDC 14 - - - - 11 25 
2 NSC 14 - 11 - - - 25 
3 S1 14 11 - - - - 25 
4 EPC 14 - - 11 - - 25 
5 PC 14 - - - 11 - 25 
 
 
3.2.3 Annealing Temperature Determination  
3.2.3.1 Temperature Gradient PCR 
The annealing temperature was determined by running a temperature gradient PCR 
on 2 dilutions of B. parapertussis positive control as follows: an initial denaturation 
at 95ºC for 5 minutes, followed by 45 cycles of denaturation at 95ºC for 30 seconds, 
annealing at 57ºC-67ºC for 40 second and extraction at 75ºC for to see the variation 
of the product formation. According to the results, there is no significant difference 
in PCR efficiency for the temperature ranges tested. The final temperature of 61ºC 
was selected in line of the condition in the existing B. pertussis PCR.    
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3.2.4 Specificity of the B. parapertussis PCR 
3.2.4.1 Testing the B. parapertussis PCR Assay against B. pertussis 
Specificity of the B. parapertussis PCR assay was determined by testing the assay 
against different dilutions of B. parapertussis, and known positive and negative 
patient samples for B. pertussis. The results showed only positive band in B. 
parapertussis dilutions, as presented in figure 3.2. Known positive samples for B. 
pertussis showed no band on the gel image, which indicated that this assay did not 
have any cross reaction with B. pertussis.  
 
 
 
 
 
 
 
Figure 0.2 B. parapertussis PCR assay against known positive and negative samples for B. pertussis  
 
3.2.4.2 Sequencing the Amplification Product  
The positive PCR product for B. parapertussis was sequenced to confirm the 
specificity of the B. parapertussis PCR assay.   The product was purified at CHW 
and sent to the Institute of Clinical Pathology and Medical Research at Westmead 
(ICPMR), for sequencing. The sequenced products were viewed using BioEdit 
(version 7.1.3.0) software as, shown in figure 3.3.  Sequence Alignment with the B. 
parapertussis Reference Strain (NC_002928) was shown in figure 3.4. 
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Figure 0.3 Nucleotide sequence profile for B. parapertussis 
 
 
 
 
 
 
 
 
Figure 0.4 Sequence alignment for B. parapertussis with the reference strain (NC_002928) 
 
3.2.5 Construction of B. parapertussis Inhibitor Control 
3.2.5.1 Forward and Reverse Primer Designing for Inhibitor Control 
Forward and reverse primers for synthesising the inhibitor control were designed at 
CHW. The nucleotide sequence from 781-1080 of B. parapertussis reference strain 
(NC_002928) is shown below in figure 3.5, which includes the positions of forward 
and reverse primer sequences for B. parapertussis. The mid-point was calculated 
between the first nucleotide of the forward primer and the last nucleotide of the 
reverse primer.  
Query  870046   ACTACGCCAGGATCGTCCCGCACGCAGGATCATCAAATCGAGTCGCTGGCTGCTGCTGCG  
870105 
                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
Sbjct  23             ACTACGCCAGGATCGTCCCGCACGCAGGATCATCAAATCGAGTCGCTGGCTGCTGCTGCG  
82 
  
Query  870106  CAACCGTGACAACCTGGATCGGCAGCAGGCCGTCCGGCTCGACGAATTGCTGCAAGCCAA  
870165 
                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
Sbjct  83            CAACCGTGACAACCTGGATCGGCAGCAGGCCGTCCGGCTCGACGAATTGCTGCAAGCCAA  
142 
 
Query  870166   CCAGCCGCTGCTGACGGTCTATGTCCTGCGTGACGAACTCAAACGGCTCTGG  870217 
                             |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  | 
 
 
 Chapter 3 Development and validation of PCR assays 67 
 
 
Figure 0.5 Nucleotide sequence of B. parapertussis reference strain (NC_002928) from 781-1080  
 
The sequence of forward primer is highlighted in green and the complimentary 
sequence for reverse primer in yellow, in figure 3.5. The mid-point is marked with a 
black dot. The 16 nucleotide sequence to the left of the mid-point (marked in blue), 
was used to design the forward primer for the inhibiter control, and the 16 nucleotide 
sequence to the right (marked in red), was used to design the reverse primer.  
Another 24 nucleotide sequence was designed for each primer and combined to 16 
nucleotide sequences, to produce 40 nucleotide long primers, as shown in the figure 
3.6.  Both the forward and reverse primers for the inhibitor control have a 16 
nucleotide sequence (highlighted in yellow) which is complimentary to each other. 
 
 
 
 
Figure 0.6 Forward and reverse primer pair for the inhibitor control 
 
3.2.5.2 Synthesis of Inhibitor Control for B. parapertussis 
The synthesis of the inhibitor control was performed in two PCR rounds. 10-2 
dilution of B. parapertussis positive control 1 (BPP_PC1) was used in this 
experiment.  
       
 781 CGTCTATGAC TTGTTCCATG TCGTGGCCAAGTATGGACGAGAGGTCATTG 
ATCGGGTGCG 
 841 CGTGGATCAG GCCAATCAAC TACGCCAGGA TCGTCCCGCA CGCAGGATCA 
TCAAATCGAG 
 901 TCGCTGGCTG CTGCTGCG.CA ACCGTGACAA CCTGGATCGG CAGCAGGCCG 
TCCGGCTCGA 
961 CGAATTGCTG CAAGCCAACC AGCCGCTGCT GACGGTCTAT GTCCTGCGTG 
ACGAACTCAA 
1021 ACGGCTCTGG TTCTACCAAA GACCTGCCTG GGCAAGACAA GCCTGGAACC 
BPP2- Forward Primer 
ATCAGGCTTGCGCATTGCTAGCTACAACCGTGACAACCTG 
BPP1- Reverse primer 
AATGCGCAAGCCTGATGTCAGTCACGCAGCAGCAGCCAGC 
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A) First Round PCR 
Forward primer for B. parapertussis target DNA and reverse primer for B. 
parapertussis inhibitor control were mixed together with FastStart master mix in tube 
1 as shown in table 35.  The reverse primer for B. parapertussis target DNA and the 
forward primer for B. parapertussis inhibitor control were mixed in tube 2 as shown 
in table 3.6.   
Table 0.5 Content in tube 1 for 1st round PCR 
Content 1 Sample 
H2O 5.0µl 
FastStart Master Mix 25.0µl 
Forward primer, PPF (10µM) 5.0µl 
Reverse primer, BPP1 (10µM) 5.0µl 
Total 40.0µl 
 
Table 0.6 Content in tube 2 for 1st round PCR 
Content 1 Sample 
H2O 5.0µl 
FastStart Master Mix 25.0µl 
Forward primer, BPP2 (10µM) 5.0µl 
Reverse primer, PPR (10µM) 5.0µl 
Total 40.0µl 
   
The final primer concentration of the reaction mixtures was 1µM. 10µl of BPP-PC1 
was added into both the tubes (final volume = 50µl) and the PCR performed.  The 
PCR product was detected by 1% agarose gel electrophoresis (0.6g of agarose 
powder+ 60ml+3µl 10,000X SYBR Safe DNA gel stain) for 25min at 100V. Size of 
the product 1- PPF/BPP1 (tube 1) was 138bp, and product 2- BPP2/PPR (tube 2) was 
136bp. These two products were purified using Wizard® PCR preps DNA 
purification system, according to the procedure shown in section 2.2.6. Purified 
products from 1st round PCRs are shown on a gel image in figure 3.7  
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B) Second Round PCR 
 The sample for the 2nd round PCR, was prepared by adding 20µl of PPF/BPP1 into 
20µl of BPP2/PPR (total volume 40µl). The tube was mixed thoroughly and set 
aside. The reaction mixture was prepared according to the ratio, as shown in table 
3.7.   
Table 0.7 Content in the reaction mixture for 2nd round PCR 
Content 1 Sample 
FastStart Master Mix 25.0µl 
Forward primer, PPF (10µM) 5.0µl 
Reverse primer, PPR (10µM) 5.0µl 
Total 35.0µl 
   
 The final primer concentration in the reaction mixture was 1µM. 35µl of reaction 
mixture plus 15µl of sample (PPF/BPP1+BPP2/PPR) were added to a PCR tube.  
The final volume of the PCR tube was 50µl. The amplified product was detected 
using 1% agarose gel electrophoresis for 25 min at100V. The size of the product 
(BPP- IC) was 258bp. This product was again purified using Wizard® PCR preps 
DNA purification system.  Purified product from 1st and 2nd round PCR assays were 
detected on 2% agarose gel, as shown in figure 3.7.  
 
 
600 
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200 
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PPF/BPP1 BPP2/PPR BPP_ IC 
(138bp) (136bp)  (258bp) 
 
Figure 0.7  1st and 2nd round PCR products on 2% agarose gel (1.2g of agarose powder+60ml+3µl 
10,000X SYBR Safe DNA gel stain). 
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3.2.6 Serial dilution of B. parapertussis positive and inhibitor controls 
Different combinations of serial dilutions were made of B. parapertussis positive 
control (PC) and inhibitor control (IC), to determine the optimum dilutions of both, 
PC and IC in the same assay without competing with each other. As shown in the 
figure 3.8, combinations of BPP-PC1-10-7+BPP-IC-10-9, BPP-PC1-10-6+BPP-IC-10-8 
and BPP-PC1-10-6+BPP-IC-10-7 are the most suitable for the B. parapertussis PCR 
assay. In these combinations both PC and IC bands are present in the same sample 
without competing with each other.  
 
 
Figure 0.8 Combinations of different dilutions of B. parapertussis positive control and inhibitor 
control 
 
 
3.2.7 Effect of Urea on B. parapertussis PCR with Inhibitor Control 
Urea is a PCR inhibitor that can be present in samples. This can be proved by mixing 
urea into some of the samples before processing the PCR. This is shown in table 3.8 
and figure 3.9. 
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  Table 0.8 Different combinations of B. parapertussis positive ± inhibitor control ± 1µl 5M urea 
Sample 
Number 
Sample ID BPP PC H2O BPP IC  5M 
Urea 10-7X 10-6X 10-9X 10-8X 
1 -PC, -IC, - urea - - 11µl - - - 
2 10-7X PC, -IC, - urea 8µl - 3µl - - - 
3 10-6X PC, -IC, - urea - 8µl 3µl - - - 
4 -PC, -IC, + urea - - 10µl - - 1µl 
5 10-7X PC, -IC, + urea 8µl - 2µl - - 1µl 
6 10-6X PC, -IC, + urea - 8µl 2µl - - 1µl 
7 -PC, 10-9X IC, - urea - - 9µl 2µl - - 
8 10-7X PC, 10-9X IC, - urea 8µl - 1µl 2µl - - 
9 10-6X PC, 10-9X IC, - urea - 8µl 1µl 2µl - - 
10 -PC, 10-9X IC, + urea - - 8µl 2µl - 1µl 
11 10-7X PC, 10-9X IC, + urea 8µl - - 2µl - 1µl 
12 10-6X PC, 10-9X IC, + urea - 8µl - 2µl - 1µl 
13 -PC, 10-8X IC, - urea - - 9µl - 2µl - 
14 10-7X PC, 10-8X IC, - urea 8µl - 1µl - 2µl - 
15 10-6X PC, 10-8X IC, - urea - 8µl 1µl - 2µl - 
16 -PC, 10-8X IC, + urea - - 8µl - 2µl 1µl 
17 10-7X PC, 10-8X IC, + urea 8µl - - - 2µl 1µl 
18 106X PC, 108X IC, + urea - 8µl - - 2µl 1µl 
 
 
All the samples containing urea demonstrate inhibition in PCR assays. Samples 2 and 
3 have positive bands for B. parapertussis, due to absence of urea.  Sample 5 and 6 
have no band due to presence of urea.   Sample 8 and 9 have positive bands for B. 
parapertussis positive control and inhibitor control due to absence of urea. Sample 
11 and 12 have no bands, due to presence of the urea.  Sample 14 and 15 have the 
bands for B. parapertussis positive control and inhibitor control, due to no urea 
added in the samples. Sample 17 and 18 have no bands for any product due to urea 
inhibition. These results clearly demonstrate that, urea has a major effect on PCR 
 
Figure 0.9 Effect of Urea on B. parapertussis PCR assay. The results correspond to the table 3.2.9. 
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product formation. Urea has inhibited the PCR amplification in both positive control 
and inhibitor control and demonstrates the importance of using an inhibitor control in 
an assay. If the inhibitor control is not detected in any assay it could be due an 
inhibitory agent present in the samples. Therefore, including an inhibitor control with 
each sample is very important in PCR testing as shown in the table 3.9 and excludes 
the possibility of false negative results. 
Table 0.9 PCR assay with inhibitor control, NDC-No DNA Control, NSC- No Sample Control, 
S1- Sample 1, EPC- Extraction Positive Control, PC-Positive Control 
Sa
mpl
e 
No 
Sample 
 ID 
Reaction 
Mixture 
(µl) 
Sample 
Vol  
(µl) 
NCS  
(µl) 
 
EPC 
(µl) 
PC 
(µl) 
H2O 
(µl) 
IC 
Vol 
(µl) 
Tot 
Vol 
(µl) 
1 NDC 14 - - - - 11 - 25 
 NDC+IC 14 - - - - 10 1 25 
2 NSC 14 - 11 - - - - 25 
 NSC+IC 14 - 10 - - - 1 25 
3 S1 14 11 - - - - - 25 
 S1+IC 14 10 - - - - 1 25 
4 EPC 14 - - 11 - - - 25 
 EPC+IC 14 - - 10 - - 1 25 
5 PC 14 - - - 11 - - 25 
 PC+IC 14 - - - 10 - 1 25 
 
3.3 Development of Bordetella holmesii PCR Assay 
3.3.1 Primer Designing 
The Bordetella holmesii monoplex PCR assay was developed using a published 
reverse primer and an in-house forward primer (Table 3.10). The assay was targeted 
to the B. holmesii specific hIS1001 region which occurs with up to 3-5 copies per 
genome (19).  Both the forward and the reverse primer were 20bp in length. 
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 Table 0.10 Forward and reverse primer match for B. holmesii 
Prime
r 
Sequence 
(5ʹ-3ʹ) 
Template 
strand 
Length Start Stop Tm GC
% 
Self 
Compl
-emen- 
tarity 
Sesf 3ʹ 
Compl
-emen- 
tarity 
Forw: 
(BHF) 
CGACAG
CGAGAC
AGAATC
CC 
Plus 20 64 83 60.53 60.00 3.00 1.00 
Rev: 
(BHR) 
ATAGAC
CGGGTG
CGTGTA
GA 
Minus 20 404 385 60.39 55.00 5.00 2.00 
Produc
t 
Length 
341bp 
 
Primer pair for B. holmesii produces a 341bp sequence, which is 114bp longer than 
B. parapertussis (226bp) and 187bp longer than the B. pertussis (153bp).  
 
3.3.2 Preparation of the Reaction Mixture 
The reaction mixture (RM) was prepared according to the ratio stated in the table 
3.11. PCR tubes were labelled before the start of the procedure. 14 µl of RM was 
pipetted into each PCR tube. PCR tubes were sealed and taken to PCR area to add 
samples. The final primer concentration of the reaction mixture was 0.5µM. 11µl of 
samples/H2O/NSC/EPC/PC were added to appropriate PCR tubes according to the 
labels giving a final volume of 25 µL.  
Table 0.11 Content in the reaction mixture for B. holmessi PCR 
Content 1 sample 
FastStart Master Mix 12.50µl 
Forward primer, BHF (20µM) 0.75µl 
Reverse primer, BHR (20µM) 0.75µl 
Total 14.00µl 
 
The PCR tubes were sealed to avoid contamination occurring when handling. The 
content of the PCR tubes were mixed by a gentle tap. Droplets were brought down 
by centrifuging the tube for 2 seconds. 
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3.3.3 Determination of Annealing Temperature for B. holmesii PCR 
The annealing temperature was determined by running a temperature gradient PCR 
on 2 dilutions of B. holmesii positive control according to the same protocol 
mentioned in section 3.2.3.1 for B. parapertussis. There is no significant difference 
in PCR efficiency for the temperature ranges tested for this assay. Therefor; the final 
temperature of 61ºC was selected in line of the condition in the existing B. pertussis 
PCR.    
 
3.3.4 Determination of the Specificity of B. holmesii PCR Assay 
3.3.4.1 Testing B. holmesii PCR Assay against B. parapertussis and B. pertussis 
PCR Assays  
Specificity of B. holmesii PCR assay was determined by testing the assay against 
different dilutions of B. holmesii, B. parapertussis, B. pertussis positive DNA and 
some PCR QAP samples as shown in figure 3.10. 
 
QAP A – B. pertussis positive            QAP D – B. pertussis positive       
QAP B – Negative                              QAPE – B. pertussis positive 
QAP C – B. pertussis positive             QAP F- B. pertussis positive 
 
 
Figure 0.10 Determination of the specificity of B. holmesii PCR assay. The gel image shows 
the positive samples for B. holmesii 
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According to the test results, this assay detects only B. holmesii positive DNA. It 
didn’t have any cross reaction with B. pertussis or B. parapertussis DNA.  
3.3.4.2 Sequencing B. holmesii PCR Product 
Sequencing the amplified product from the B. holmesii PCR reaction was another 
way of determining the specificity of this PCR assay. B. holmesii DNA was 
amplified using the B. holmesii specific primer pair and purified using the Wizard® 
prep DNA purification system (see section 2.2.6). The purified product was sent to 
ICPMR, Westmead Hospital for sequencing. The sequenced product was viewed in 
BioEdit (version 7.1.3.0), as shown in figure 3.11.  The sequence alignment with the 
reference strain (ANGE01000043.1) of B. holmesii was shown in figure 3.12. 
 
 
  
Figure 0.11 Nucleotide sequence profile for B. holmesii reference strain (ANGE01000043.1) 
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3.3.5 Construction of the B. holmesii Inhibitor Control 
3.3.5.1 Forward and Reverse Primer Designing for Inhibitor Control 
The inhibitor control for B. holmesii was synthesised in-house using a specifically 
designed primer pair. The nucleotide sequence from 1-516 in B. holmessi genome 
(ANGE01000043.1) is shown in figure 3.13. The 20 nucleotide sequence marked in 
red is the forward primer sequence for B. holmesii target DNA. The sequence marked 
in purple is the complementary sequence for the reverse primer in B. holmesii 
genome.  
Query  64   CGACAGCGAGACAGAATCCCGTGCAGATAGGCTTTTAGCTTGAGCGCGAAGTGAGCCAAG  123 
                     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |   
Sbjct  312   CGACAGCGAGACAGAATCCCGTGCAGATAGGCTTTTAGCTTGAGCGCGAAGTGAGCCAAG  253 
 
Query  124  GCGGCGATGCCGCTGCCCTGAGCCTGTTGCAGCCAGTGATCCCATGCCTGGCGGGCGTAG  183 
                      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  | 
Sbjct  252   GCGGCGATGCCGCTGCCCTGAGCCTGTTGCAGCCAGTGATCCCATGCCTGGCGGGCGTAG  193 
 
Query  184   CCGGGGTGTTGGTAGAACCACAGCTGTTTGAGCTCATCGCGCATCAGATAAGCGGTGAGC  243 
                     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   | 
Sbjct  192   CCGGGGTGTTGGTAGAACCACAGCTGTTTGAGCTCATCGCGCATCAGATAAGCGGTGAGC  133 
 
Query  244  AAGGGCTGGTTGGCCTGGAGCAACTCGTCCAACTTTACCGATTGGCACGGATCGAGGTTT  303 
                      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   
Sbjct  132   AAGGGCTGGTTGGCCTGGAGCAACTCGTCCAACTTTACCGATTGGCACGGATCGAGGTTT  73 
 
Query  304  TTGCGATTGCGCAGCAGTAGCCAGCGACTGGACTTGATCACCCGGCGGGCCGGCTTGTC  362 
                      |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |  |  | 
Sbjct  72     TTGCGATTGCGCAGCAGTAGCCAGCGACTGGACTTGATCACCCGGCGGGCCGGCT-GTC  15 
                                                    
Figure 0.12 Sequence alignment with the B. holmesii reference strain (ANGE01000043.1) 
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The mid-point was calculated between the 1st nucleotide of the forward primer 
(position 64) and the last nucleotide of the complimentary sequence to the reverse 
primer (position 404). The mid-point is marked with a black dot in this sequence. 
The 16 nucleotide sequence to the left side (highlighted in yellow) was used to 
design the forward primer of the inhibitor control. The 16 nucleotide sequence to the 
right side (highlighted in green) was used to design the reverse primer of the 
inhibitor control. Another 28 nucleotide sequence was design to combine with each 
primer which produces a 40bp long IC primer pair.  
The primer pair for the B. holmesii inhibitor control is shown below in figure 3.14. 
The 16 nucleotide sequences highlighted in yellow in both primers were designed to 
be complimentary to each other.     
 
 
 
 
 
 
1CGCCGCTTGATGACCTTGATAGTGTTGTTGATGCCCTCGACGATGCTGGTGTTGAGCCG
GTGGCGACAGCGAGACAGAATCCCGTGCAGATAGGCTTTTAGCTTGAGCGCGAAGTG
AGCCAAGGCGGCGATGCCGCTGCCCTGAGCCTGTTGCAGCCAGTGATCCCATGCCTGGC
GGGCGTAGCCGGGGTGTTGGTAGAACCACAGCTGTTTGAGCTCATCGCGCATCAGAT
A.AGCGGTGAGCAAGGGCTGGTTGGCCTGGAGCAACTCGTCCAACTTTACCGATTGGC
ACGGATCGAGGTTTTTGCGATTGCGCAGCAGTAGCCAGCGACTGGACTTGATCACCCGG
CGGGCCGGCTTGTCGTGCCGCAACTGGTTCGCTTGGTCTACACGCACCCGGTCTATCA
CTTCACGGCCGTACTTGGCCACGACGTGGAACAGGTCGTAGCGATCTCGGCGTTGGGGC
AGTTGGCCTGGATCTCCAACTCGTAGGCGGTG 516  
Figure 0.13 Nucleotide sequence from 1-516 in B. holmesii reference strain (ANGE01000043.1) 
 
 
BH2-Forward primer 
ATCAGGCTTGCGCATTGCTAGCTAGCTAAGCGGTGAGCAAGGGC 
 
 
BH1-Reverse primer 
AATGCGCAAGCCTGATGTCAGTCAGTCATATCTGATGCGCGATG 
 
Figure 0.14 Forward and reverse primer pair for the B. holmesii inhibitor control 
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3.3.5.2 Synthesis of Inhibitor Control for B. holmesii 
Synthesis of B. holmessi inhibitor control was performed in two steps as mentioned 
below. 10-2 dilution of B. holmesii DNA (BH-PC1) was used in the first round PCR, 
which was extracted from the original culture (312-0546) grown in The Department 
of Microbiology at CHW.  
A) First Round PCR 
The first round consists of 2 different PCR assays. The forward primer for B. 
holmesii target DNA and reverse primer for B. holmesii inhibitor control were mixed 
together with FastStart master mix in tube 1 as described in table 3.12.  Reverse 
primer for B. holmesii target DNA and forward primer for B. holmesii inhibitor 
control were mixed in tube 2 as shown in table 3.13. 
Table 0.12 Content in tube 1 for 1st round PCR 
Content µl per sample 
H2O   5.0 
FastStart Master Mix 25.0 
Forward primer, BHF (10µΜ)  5.0 
Reverse primer, BH1 (10µΜ)  5.0 
Total 40.0 
       
 
      
Table 0.13 Content in tube 2 for 1st round PCR 
Content µl per sample 
H2O   5.0 
FastStart Master Mix 25.0 
Forward primer, BH2 (10µΜ)  5.0 
Reverse primer, BHR (10µΜ)  5.0 
Total 40.0 
 
Final primer concentration of the reaction mixture was 1 µM. The tubes were 
immediately taken to the PCR area to add samples. 10 µL of 10-2 dilution of B. 
holmesii positive control DNA was added into each tube. The contents of the tubes 
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were mixed by gently tapping and briefly centrifuged to bring all the droplets down, 
prior to performing the PCR. 
The amplified PCR product was detected on 1% agarose gel electrophoresis (0.6g 
agarose powder+ 60ml buffer+ 10,000 SYBR Safe DNA gel stain) for 25mins at 
100V. The product size in tube 1 (BHF/BH1) was 170bp and tube 2 (BH2/BHR) was 
171bp. These products were purified from the gel using Wizard® prep DNA 
purification system as mentioned in section 2.2.6. The purified products were 
labelled and stored at -20⁰C for further processing.  
B) Second Round PCR 
 Two products from the 1st round PCR were used in 2nd round PCR. The sample was 
prepared by adding 20µl of product 1 (BHF/BH1) to 20µl of product 2 (BH2/BHR) 
for the 2nd round. The reaction mixture was prepared as mentioned in the table 3.14. 
Table 0.14 Content of the reaction mixture for 2nd round PCR 
Content µl per sample 
FastStart Master Mix 25.0 
Forward primer, BHF (10µΜ) 5.0 
Reverse primer, BHR (10µΜ) 5.0 
Total 35.0 
 
15µl of sample was added into the reaction mixture, mixed and centrifuged before 
the PCR. The product of the 2nd round PCR was detected on 1% agarose gel and 
purified using the Wizard® prep DNA purification system. The product size was 
391bp and was used as the inhibitor control for B. holmesii in further experiments.  
 
3.3.6 Serial Dilution of B. holmesii Positive Control and Inhibitor Control  
Combinations of B. holmesii positive control and inhibitor control were tested, to 
determine the most suitable combination to carry out further experiments. Serial 
 Chapter 3 Development and validation of PCR assays 80 
dilutions of the positive control (BH-PC 10-9&10-10) and the inhibitor control (BH-IC 
10-14- 10-16) were prepared separately and combined as mentioned in figure 3.15.   
According to the results, the most suitable combinations for B. holmesii PCR assay 
are BH-PC10-9 + BH-IC 10-16, PC10-9+ BH-IC 10-15 and PC10-9+ BH-IC 10-14.   
 
 
Figure 0.15 Combinations of BH-PC and BH-IC 
 
3.3.7 Effect of Urea (200mM) on B. holmesii PCR Assay with Inhibitor Control  
The concentration of urea in the final reaction mixture was 200µM. It was made by 
adding 1µl of 5mM urea to 25µl of final PCR reaction mixture. 10-9 B. holmesii 
positive control dilution and 10-15 inhibitor control dilution were used in this 
experiment (Figure 3.16). Combinations of positive control, inhibitor control and 
urea are stated in the table 3.15. 
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 Table 0.15 Effect of urea on B. holmesii PCR assay with inhibitor control 
Sample 
Number 
Sample ID BH PC H2O BH IC  5M 
Urea 10-19X 10-15X 
1 -PC, -IC, - urea - 10µl - - 
2 10-9X PC, -IC, - urea 8µl 2µl - - 
3 -PC, -IC, + urea - 9µl - 1µl 
4 10-9X PC, -IC, + urea 8µl 1µl - 1µl 
5 -PC, 10-15X IC, - urea - 9µl 1µl - 
6 10-9X PC, 10-15X IC, - urea 8µl 1µl 1µl - 
7 -PC, 10-15X IC, + urea - 8µl 1µl 1µl 
8 10-9X PC, 10-15X IC, + urea 8µl - 1µl 1µl 
 
 
 
 
Figure 0.16 Urea effect on B. holmesii PCR assay with inhibitor control; corresponding results to the 
table 3.3.9. 
 
According to the results of this experiment, no sample containing urea produced any 
product during the PCR amplification. This experiment proves the importance of 
including an inhibitor control with each sample in a PCR assay. Any existing PCR 
inhibition can be detected by this method. 
 
3.4 Development of B. pertussis, B. parapertussis and B. holmessi 
Multiplex PCR Assay  
3.4.1 Introduction 
Bordetella multiplex PCR assay was developed by combining B. pertussis, B. 
parapertussis and B. holmesii PCR assay. All three monoplex PCR assays were 
optimised with same PCR amplifications conditions at the initial stage of PCR 
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development. Therefore, the multiplex PCR assay was developed using the same 
PCR conditions.  
 
3.4.2 Monoplex Vs Multiplex 
Primer sets for monoplex PCR assays were stored separately at -20⁰C. A new 
forward and reverse primer sets were made for the multiplex PCR assay by 
combining all three forward primers and reverse primers separately. 10µM of B. 
pertussis, B. parapertussis and B. holmessi forward primer dilutions were combined 
together to form forward primer set (FPS), and 10µM of all the reverse primer 
dilutions were combined to form reverse primer set (RPS). These primer sets were 
labelled with the name, date of preparation and concentration, and stored at -20⁰C in 
the pre PCR area. Combinations of positive controls and inhibitor controls used in 
monoplex and multiplex PCR assay are mentioned below in table 3.16.  
Table 0.16 Combinations of PCs and ICs used in monoplex and multiplex PCR assays 
PCR assay Code Positive Control (PC) Inhibitor Control (IC) 
BP-PC BPP-PC BH-PC BP-IC BPP-
IC 
BH-IC 
B. pertussis 
Monoplex 
BP 10-4 - - 10-3 - - 
B. Parapertussis 
Monoplex   
BPP - 10-6 - - 10-8 - 
B. holmesii 
Monoplex 
BH - - 10-9 - - 10-15 
B. pertussis/    
B. parapertussis/ 
B. holmesii 
Multiplex 
BP/BPP/BH 10-4 10-6 10-9 10-3 10-5 10-12 
Note 
• 33.3µl of BP-PC 10-4+33.3µl of  BPP-PC 10-6 + 33.3µl of BH-PC 10-9 = 100µl of 
BP/BPP/BH PCs 
• 10µl of BP-IC 10-3+ 10µl of BPP-IC 10-5+ 10µl of BH-IC 10-12 + 70µl H2O = 
100µl of BP/BPP/BH ICs 
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3.4.2.1 Preparation of the Reaction Mixture for Multiplex PCR Assay 
 The reaction mixture for the multiplex PCR was prepared according to the following 
ratio stated in table 3.17. Final primer concentration of the reaction mixture was 
0.5 µΜ. 15µl of reaction mixture was added into each tube and  9µl of BP/BPP/BH 
PCs or NDC were added to appropriate tubes. 1 µl of BP/BPP/BH ICs or H2O were 
added to appropriate tubes (final volume 25µl). 
Table 0.17 Content of the reaction mixture for multiplex PCR 
Content µl per Sample 
FastStart Master Mix 12.50 
Forward Primers, FPS (10µΜ) 1.25 
Reverse Primers, RPS (10µΜ) 1.25 
Total 15.00 
 
3.4.2.2. Comparison between Monoplex and Multiplex PCRs 
 A comparison between the three monoplex PCRs and the multiplex PCR is shown in 
figure 3.17. All three bands for PCs and ICs separately, and all 6 bands for PCs and 
ICs together were displayed in the multiplex PCR assay.   
Figure 0.17 Monoplex Vs Multiplex 
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3.4.3 Sensitivity and Specificity of the Multiplex PCR Assay 
The sensitivity and specificity of the multiplex PCR (mPCR) assay was determined 
by, comparison of the multiplex PCR assay against the culture (gold standard). 
Bordetella culture was performed for B. pertussis and B. parapertussis in The 
Department of Microbiology at CHW as a routing test. The results of Bordetella 
culture were compared with the multiplex PCR results to analyse sensitivity and 
specificity of B. pertussis and B. parapertussis. Sensitivity and specificity analysis 
were not done for B. holmesii as no diagnostic culture method for B. holmesii from 
respiratory specimens was performed at CHW.  The results are displayed in figures 
3.18 and 3.19 respectively for B. pertussis and B. parapertussis. 
 
Figure 0.18 Sensitivity and specificity, PPV and NPV of the multiplex PCR for B. pertussis 
According to the results, multiplex PCR assay for Bordetella shows high sensitivity 
(100.0%) and specificity (98.3%) comparing with Bordetella culture for B. pertussis. 
 
 
B. pertussis Culture 
Positive Negative 
mPCR Positive 4 (TP) 6 (FP) 
Negative 0 (FN) 342 (TN) 
 
Sensitivity  100.0% 
Specificity 98.3% 
PPV 40.0% 
NPV 100.0% 
 
B. parapertussis Culture 
Positive Negative 
mPCR Positive 2 (TP) 8 (FP) 
Negative 0 (FN) 344 (TN) 
 
Sensitivity  100.0% 
Specificity 97.7% 
PPV 20.0% 
NPV 100.0% 
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Figure 0.19 Sensitivity and specificity, PPV and NPV of the multiplex PCR for B. parapertussis 
 
According to these results the sensitivity and specificity of the multiplex PCR assay 
were very high compared with the gold standard, culture.   The multiplex PCR assay  
shows high sensitivity (100.0%) and specificity (97.7%) for B. parapertussis 
compared with the Bordetella culture.  
 
3.4.4 Limit of Detection of Multiplex PCR Assay  
Limit of Detection (LOD) is the minimum amount of DNA that can be detected by a 
PCR test. LOD of the Bordetella multiplex PCR assay was determined by counting 
the actual colony forming units of the highest dilution which was detected by the 
multiplex PCR assay.  
3.4.4.1 Sample Preparation 
 A few colonies were picked from a freshly grown culture for each Bordetella 
species and suspended in 1ml of brain heart infusion broth separately. The tubes 
were labelled with the Bordetella species and the date. This sample was called the 
stock. DNA was extracted from 400µl of the original stock for each species and 
stored in -20⁰C.  
3.4.4.2 Limit of Detection for B. pertussis in Multiples PCR Assay 
Serial dilutions from 10-2 to 10-10 were performed from the original stock of B. 
pertussis and plated in triplicates. The plating procedure is shown in the figure 3.20. 
The plates were incubated at 35⁰C for 5-7 days for colony formation.  
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Figure 0.20 Serial dilution and plating of B. pertussis 
 
Plates were observed daily from the 2nd day to track the growth of colonies. Plates 
were read on the 7th day. Results of this experiment are shown in the table 3.18 
below.  
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Table 0.18 Number of colony forming (CFU) units for B. pertussis dilutions 
B. pertussis Dilution Plate Number CFU /100µl Average 
CFU/100µl 
10-2 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-4 
1 Uncountable 
Uncountable 
2 Uncountable 
3 Uncountable 
10-6 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-8 
1 100+ 
100+ 2 100+ 
3 100+ 
10-10 
1 26 
25  2 24 (see figure 3.4.6) 
3 25 
 
Simultaneously, a serial dilution of stock DNA (10-9-10-13) was performed and tested 
using multiplex PCR assay to determine the level of detection (Cut-off) of the 
multiplex PCR assay for B. pertussis (refer Figures 3.21 and 3.22). 
 
Figure 0.21 Serial dilution B. pertussis stock DNA 
 
 
 
 
 Chapter 3 Development and validation of PCR assays 88 
 
Figure 0.22 B. pertussis plate number 2 with 24 CFU/100µl. The picture represents 7 day old B. 
pertussis culture on charcoal agar which was grown in The Department of Microbiology at CHW. 
  
The highest dilution of B. pertussis DNA which was distinguishable by the 
Bordetella multiplex PCR (mPCR) was 10-12. Calculations were done as shown 
below. 
Calculations: 
1. In culture, B. pertussis was detected at 25 cfu in 100µL working stock at  
10-10 dilution;  
Hence, the concentration in the original stock = 25 ÷ 0.1 × 1010 = 2.5 x 1012 
cfu/mL 
2. In the DNA extraction, 400µL original stock (i.e. 2.5 × 1012 × 0.4 = 1012 cfu) 
was extracted into 50 µL of  eluate; 
Hence, the concentration in the eluate = 1012 ÷ 0.05 = 2 x 1013 cfu/mL 
3. In the PCR, 10CRof eluate (i.e. 2 × 1013 × 0.01 = 2 × 1011 cfu) was used, 
resulting in a detection cut off at the 10-12 dilution; 
Hence, LOD for PCR = 2 × 1011 × 10-12 = 0.2 cfu 
Therefore, the LOD for B. pertussis in the multiplex PCR assay, = 1CFU   
 
 
3.4.4.3 Limit of detection for B. parapertussis in multiplex PCR Assay 
 
Serial dilution of (10-1-10-5) B. parapertussis was prepared from the original stock 
and plated on charcoal agar plates in triplicate, as shown in figure 3.23.  
B. parapertussis DNA was extracted from 400µl of the original stock and serial 
dilutions were prepared from 10-2-10-14. These dilutions were tested in the multiplex 
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PCR assay, to determine the highest dilution of B. parapertussis DNA which can be 
detectable by this PCR test.    
 
 
Figure 0.23 Serial dilution and plating for B. parapertussis 
 
Plates were incubated at 35⁰C in an aerobic jar and colony forming units were 
counted at day 7. The number of colony forming units corresponding to each dilution 
is stated in table 3.19. 
 
Table 0.19 Number of colony forming units for B. parapertussis in each dilution 
B. parapertussis 
Dilution 
Plate Number CFU /100µl Average 
CFU/100µl 
10-1 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-2 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-3 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-4 
1 100+ 
100+ 2 100+ 
3 100+ 
10-5 
1 31 
28 2 27 
3 27 (see figure 3.4.9) 
 
The multiplex PCR results for the serial dilution of B. parapertussis DNA are shown 
in figures 3.24 and 3.25. B. parapertussis positive control dilutions were prepared 
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from 10-2- 10-14. According to these results the highest dilution of B. parapertussis 
DNA that can be detected in the multiplex PCR is 10-7. This value is used in 
calculations to detect level of detection (cut-off point) of multiplex PCR for B. 
parapertussis.  
 
Figure 0.24 mPCR results for the serial dilution of B. parapertussis DNA 
 
 
Figure 0.25 B. parapertussis plate number 3 with 27 CFU/100µl. This picture is 7day old B. 
parapertussis culture on charcoal agar plate which was grown at Microbiology Department, CHW. 
  
Calculations; 
Highest dilution of B parapertussis DNA detectable by multiplex PCR assay (cut off 
point) = 10-7 
1. In culture, B. parapertussis was detected at 28 cfu in 100µL working stock at 
10-5 dilution;  
Hence, the concentration in the original stock = 28 ÷ 0.1 × 105 = 2.8 x 107 
cfu/mL 
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2. In the DNA extraction, 400µL original stock (i.e. 2.8 × 107 × 0.4 = 1.12 × 107 
cfu) was extracted into 50 µLof eluate; 
Hence, the concentration in the eluate = 1.12 × 107 ÷ 0.05 = 2.24 × 108 
cfu/mL 
3. In the PCR, 10µL of eluate (i.e. 2.24 × 108 × 0.01 = 2.24 × 106 cfu) was used, 
with the detection cut off at 10-7 dilution; 
Hence, LOD for PCR = 2.24 × 106 × 10-7 = 0.224 cfu 
Therefore, the LOD for B. parapertussis in multiplex PCR assay = 1CFU 
 
3.4.4.4 Limit of Detection for B. holmesii in Multiplex PCR Assay 
Serial dilution of B. holmesii from the original stock was performed and plated onto 
charcoal agar plates in triplicates. Plates were incubated for 7 days at 35⁰C in an 
aerobic jar. These culture plates were rapped with parafilm tapes to avoid 
contamination with fungus. The procedure for plating is shown in figure 3.26. The 
colony forming units were counted in each plate which is mentioned in table 3.20.  
 
 
Figure 0.26 Serial dilution and plating of B. holmesii 
 
B. holmesii stock was prepared from a very fresh 2 day old culture due to viability 
issues. The bacteria were very sensitive and susceptible to die off. B. holmesii need 
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specialised medium to grow. However, we were able to grow B. holmesii on charcoal 
agar successfully.  
 
Table 0.20 Colony forming units for each dilution of B. holmesii 
B. holmesii Dilution Plate Number CFU /100µl Average 
CFU/100µl 
10-2 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-4 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-6 
1 Uncountable 
Uncountable 2 Uncountable 
3 Uncountable 
10-8 
1 100+ 
100+ 2 100+ 
3 100+ 
10-9 
1 35 
36 2 37 (see figure 3.4.12) 3 CFU were not visible 
due to fungal growth 
 
DNA was extracted from 400µl of original stock and serial diluted to test with the 
mPCR to determine the cut-off point for B. holmesii. Serial dilution of 10-6-10-13 was 
made and tested in the multiplex PCR. Results of this experiment are shown in 
figures 3.27 and 3.28.  
 
Figure 0.27 mPCR results for B. holmesii serial dilution 
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Figure 0.28 B. holmesii plate number 2 with 37CFU/100µl. the picture is 7 day old B. holmesii culture 
on charcoal agar. It was grown in The Department of Microbiology at CHW. 
 
Calculations; 
Highest dilution of B .holmesii DNA detectable by the multiplex PCR assay (cut off 
point) = 10-11 
1. In culture, B. holmesii was detected at 36 cfu in 100µL working stock at 10-9 
dilution;  
Hence, the concentration in the original stock = 36 ÷ 0.1 × 109 = 3.6 x 1011 
cfu/mL 
2. In the DNA extraction, 400µL original stock (i.e. 3.6 x 1011 × 0.4 = 1.44 x 
1011 cfu) was extracted into 50 µL eluate; 
Hence, the concentration in eluate = 1.44 x 1011 ÷ 0.05 = 2.88 x 1012 cfu/mL 
3. In the PCR, 10µL eluate (i.e. 2.88 x 1012 × 0.01 = 2.88 × 1010 cfu) was used, 
with the detection cut off at 10-11 dilution; 
Hence, LOD for PCR = 2.88 × 1010 × 10-11 = 0.288 cfu 
Therefore, the LOD for B. holmesii in the multiplex PCR assay,=1CFU 
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3.5 Bordetella Multiplex PCR Assay Validation 
The Bordetella multiplex PCR assay validation was done by testing clinical samples 
for 2 months. The Bordetella multiplex PCR assay was conducted parallel to the  
B. pertussis, B. parapertussis and B. holmesii monoplex PCR assays to determine the 
sensitivity of multiplex PCR assay against its own monoplex PCR assays for each 
species. All the respiratory specimens received in The Department of Molecular 
Pathology, during 14th Nov to 31st Dec 2012 for Bordetella screening, were tested for 
validation. 54 respiratory samples were tested in total and, 2 B. pertussis positives 
and no B. parapertussis and B. holmesii were detected. These 2 B. pertussis positive 
samples were detected by both monoplex and multiplex PCR assays. Results 
achieved from the multiplex PCR assay for three Bordetella species were similar to 
the results of their own monoplex PCR assays.  This shows the sensitivity and 
specificity of both the monoplex and the multiplex PCR assays were at the same 
level. Every assay conducted during the period of validation included no DNA 
control, no sample control, positive control, extraction positive control, clinical 
samples and inhibitor control with each assay run.  
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3.6 Discussion  
PCR assay development and validation, analysis of LOD and specificity, and 
synthesis of inhibitor controls were discussed in this chapter. I have successfully 
developed highly sensitive and specific monoplex PCR assays for B. parapertussis 
and B. holmesii and a multiplex PCR assay for B. pertussis, B. parapertussis and B. 
holmesii. Inhibitor controls for B. parapertussis and B. holmesii were synthesised 
using molecular engineering techniques, at CHW and combined with each monoplex 
PCR assays. 
Primers for all in-house developed PCRs were designed using the primer blast 
programme provided by NCBI. BP1/BP4 primer pair for B. pertussis, PPF/ PPR for 
B. parapertussis and BHF/BHR for B. holmesii was used in each monoplex and 
multiplex PCR assay. BP5/BP6 primer pair for B. pertussis inhibitor control, 
BPP1/BPP2 for B. parapertussis and BH1/BH2 for B. holmesii was used. The 
annealing temperature was set at 61⁰C and same amplification conditions were used 
in all four PCR assays. Sensitivity was analysed for each PCR assay and detection 
levels (cut-off point) were determined and the level of sensitivity for detection of the 
individual Bordetella species in the monplex and multiplex PCR assays was 
comparable.   
The specificity of each monoplex PCR assay was tested against B. pertussis, B. 
parapertussis, and B. holmesii and amplified products were sequenced to determine 
product purity. They were all found to be highly specific. The PCR assay validations 
were done by testing clinical samples over 2 months period, prior to the Bordetella 
clinical study. 
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Chapter 4 Detection of Bordetella in respiratory specimens using 
multiplex PCR assays 
 
4.1 Introduction 
The aim of this chapter is to investigate Bordetella infections in a paediatric setting 
at The Children’s Hospital at Westmead. Clinical samples were tested over a year 
from Jan 2013 to Dec 2013. Respiratory specimens with Bordetella pertussis testing 
requested were tested using the newly developed multiplex PCR assay. The 
Bordetella mutilpex PCR assay and the monoplex PCR assays were performed in 
parallel over a period of 2 months to compare the sensitivity and specificity and to 
determine the positive and negative predictive values of the assays. The results of 
cultures for B. pertussis and B. parapertussis performed at The Department of 
Microbiology were compared with the multiplex PCR assay to determine its 
sensitivity and specificity. Positive and negative samples identified in this study were 
stored separately, to avoid contamination. Age distribution, gender distribution, rate 
of Bordetella infection for each species and sample types were analysed.   
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4.2 Results of Bordetella pertussis 
4.2.1 Detection of Bordetella pertussis  
Over the one year period, 464 respiratory specimens including 392 nasopharyngeal 
aspirates, 70 nasopharyngeal swabs and 2 endotracheal aspirates were tested using 
the multiplex Bortetella PCR assay. Of the 464 specimens tested, 13 specimens 
(2.8%) were positive for B. pertussis in the multiplex PCR assay and 14 specimens 
(3.0%) were positive using the monoplex PCR assay, and 1 specimen was positive 
for both B. pertussis and B. parapertussis. Only NPA specimens tested by PCR 
(n꞊346) were cultured and other NP swabs were excluded due to the unsuitability of 
the transport medium, as it contains antibiotics which inhibit the growth of 
Bordetella species.  Therefore, only the 346 nasopharyngeal aspirates were cultured. 
Of the 346 specimens cultured, 4 specimens (1.2%) were positive for B. pertussis. 
The sensitivity and specificity of the Bordetella multiplex PCR assay for B. pertussis 
were compared with the B. pertussis culture and the monoplex PCR assay. 
Comparison between B. pertussis monoplex PCR assay and Bordetella multiplex 
PCR assay is shown in table 4.1. 
 
Table 0.1 B. pertussis monoplex Vs Bordetella multiplex 
B. pertussis Monoplex PCR 
Positive Negative 
Multiplex PCR Positive 13 0 13 
Negative 1 450 451 
14 450 464 
 
The sensitivity of the Bordetella multiplex PCR assay for detection of B. pertussis, 
comparing with the B. pertussis monoplex PCR assay as the “gold” reference 
standard, was 93.0% (95% CI=68.5-98.7%) and the specificity was 100.0% (95% 
CI=99.2-100.0%). The positive predictive value (PPV) was 100.0% (95% CI= 77.19-
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100%) and negative predictive value (NPV) was 99.8% (95% CI= 98.8-100.0%). 
Accuracy of this test was 99.8%.   
Comparison between Bordetella multiplex PCR assay and Bordetella culture (gold 
stand) is shown in table 4.2. 
 Table 0.2 B. pertussis culture Vs multiplex PCR. 
B. pertussis 
Culture 
Positive Negative 
Multiplex PCR Positive 4 6 10 
Negative 0 342 342 
4 348 352 
The sensitivity of the multiplex PCR assay for B. pertussis, compared with culture as 
“gold” standard, was 100.0% (95% CI= 51.0-100.0%) and specificity was 98.3% 
(95% CI= 96.3-99.2%). The PPV was 40.0% (95% CI= 17.0-62.7%) and the NPV 
was 100.0% (95% CI= 98.9-100.0%). The accuracy of this test was 98.3%. The 
results for B. pertussis culture and the B. pertussis monoplex PCR assay were 
provided by The Department of Microbiology at CHW. 
          
4.2.2 Rate of infection for B. pertussis in 2013 
B. pertussis was found in all the months except August, September, and December in 
2013. The highest rate of infection recorded was in January 2013 (8.3%). The 
infection shows high rates in first 3 months of the year (8.3%, 8.0% and 7.7% 
respectively) and variable rates in the other months. The infection rates are displayed 
in the table 4.3 and figure 4.1.  
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Figure 0.1 Graph of rate of infection for B. pertussis in 2013 
 
 
4.2.3 Patient Demographics for B. pertussis Infection 
4.2.3.1 Age Distribution of Infection 
Age of patients with B. pertussis infection ranged from 5 month to 8 years with the 
median age of 1.25 years. The rate of infection for each age group is displayed in the 
 Table 0.3 Rate of infection for B .pertussis in 2013 
Month Total no of Specimens 
No of BP 
Positive 
BP Infection 
Rate 
Jan 12 1 8.33% 
Feb 25 2 8.00% 
Mar 26 2 7.69% 
Apr 53 1 1.89% 
May 63 2 3.17% 
Jun 65 2 3.08% 
July 50 1 2.00% 
Aug 51 0 0.00% 
Sept 44 0 0.00% 
Oct 26 1 3.85% 
Nov 22 1 4.55% 
Dec 27 0 0.00% 
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table 4.4.  The highest infection rate for B. pertussis (9.5%), was demonstrated in the 
age group of 3-4 years. The incidents of infections were low in children over 4 years 
old. The graph of age distribution is displayed in figure 4.2.  
 
 
 
Figure 0.2 Graph of age distribution of B. pertussis infection 
 
4.2.3.2 Gender Distribution 
The Incidence of B. pertussis infection in females was 9 out of 209 (4.0%) and the 
incidence in males was 4 out of 255(1.6%). The gender distribution is displayed in a 
pie chart at figure 4.3.  
Table 0.4 Age distribution of B. pertussis infection  
Age groups 
Total patients in 
the age group  
No of 
Positive 
Rate of 
infection  
0 to 1 269 5 1.86% 
1 to 2 63 3 4.76% 
2 to 3 38 2 5.26% 
3 to 4 21 2 9.52% 
4 to 5 23 0 0.00% 
>5 50 1 2.00% 
464 13 
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Figure 0.3 Gender distribution of B. pertussis infection 
 
 
4.3 Detection of Bordetella parapertussis 
4.3.1 B. parapertussis Results 
During the 1 year period, 464 specimens were tested for B. parapertussis using the 
Bordetella multiplex PCR assay. 13 specimens including 10 NPAs and 3 NP swabs, 
(2.8%), were positive for B. parapertussis DNA, among these, 1 specimen had a co-
infection with B. pertussis. Culture for B. parapertussis was performed on 346 
nasopharyngeal aspirates. From the 346 specimens tested, 2 specimens (0.6%) were 
positive for B. parapertussis.  (Table 4.5) 
The sensitivity of the multiplex PCR assay for B. parapertussis was determined by 
testing 60 specimens with the multiplex PCR assay and the B. parapertussis 
monoplex PCR assay. The results are displayed on table below.  
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 Table 0.5 Bordetella multiplex PCR assay Vs B. parapertussis monplex PCR assay 
B. parapertussis Monoplex PCR 
Positive Negative 
Multiplex PCR Positive 1 0 1 
Negative 0 59 59 
1 59 60 
 
The sensitivity of the Bordetella multiplex PCR assay for B. parapertussis, 
comparing with the B. parapertussis monoplex PCR assay as the reference standard, 
was 100.0% (95% CI=20.7-100.0%) and the specificity was 100.0% (95% CI=93.9-
100.0%). The positive predictive value (PPV) was 100.0% (95% CI= 20.7-100.0%) 
and negative predictive value (NPV) was 100.0% (95% CI= 93.9-100.0%). Accuracy 
of this test was 100.0%.   
Comparison of Bordetella multiplex PCR assay with Bordetella culture for B. 
parapertussis is shown in table 4.6.  
 
Table 0.6 Bordetella multiplex PCR Vs Bordetella culture for B. parapertussis 
B. parapertussis 
Culture 
Positive Negative 
Multiplex PCR Positive 2 8 10 
Negative 0 336 336 
2 344 346 
 
The sensitivity of the multiplex PCR assay for B. parapertussis, compared with the 
culture as the “gold” standard, was 100.0% (95% CI= 34.2-100.0%) and the 
specificity was 97.7% (95% CI= 95.6-98.8%). The PPV was 20.0% (95% CI= 5.7-
51.0%) and the NPV was 100.0% (95% CI= 98.9-100.0%). The accuracy of this test 
was 97.7%. The results for B. parapertussis culture were provided by The 
Department of Microbiology at CHW.  
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4.3.2 Rate of infection for B. parapertussis in 2013 
B. parapertussis infection was detected in all the months except February, October 
and December in 2013. The highest rate of infection was reported in January 2013 
(8.3%). The infection shows slightly high rates in first half of the year (see table 4.7) 
and figure 4.4).  
 
 
 
 
 
 
 
Table 0.7 Rate of infection for B. parapertussis infection in 2013 
Month Total no of 
Specimens 
No of BPP 
Positive 
BPP Infection 
Rate 
Jan 12 1 8.33% 
Feb 25 0 0.00% 
Mar 26 1 3.85% 
Apr 53 2 3.77% 
May 63 2 3.17% 
Jun 65 3 4.62% 
July 50 1 2.00% 
Aug 51 1 1.96% 
Sept 44 1 2.27% 
Oct 26 0 0.00% 
Nov 22 1 4.55% 
Dec 27 0 0.00% 
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Figure 0.4 Graph of rate of infection for B. parapertussis in 2013 
 
 
4.3.3 Patient Demographics for B. parapertussis Infection 
4.3.3.1 Age Distribution of Infection 
The age of patients with B. parapertussis infection ranged from 7 month to 5 years 
with the median age of 1.25 years (15 months). The incidence of infection for each 
age group is shown in the table 4.8.  The highest infection incidence for B. 
parapertussis (13.0%) was detected in the age group of 4-5 years. The incidence of 
infections was low in the age groups of 3-4 years and children over 5 years old. The 
graph of age distribution is displayed in figure 4.5.  
Table 0.8Age distribution of B. parapertussis infection  
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Age 
groups 
Total no of patient 
in the age group 
No of 
positives 
Rate of 
infection 
0 to 1 269 4 1.49% 
1 to 2 63 5 7.94% 
2 to 3 38 1 2.63% 
3 to 4 21 0 0.00% 
4 to 5 23 3 13.04% 
>5 50 0 0.00% 
464 13 
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Figure 0.5 Age distribution of B. parapertussis infection 
 
4.3.3.2 Gender Distribution 
The incidence of B. parapertussis infection in males was 11 out of 255 (4.0%) and 
the incidence in females was 2 out of 209 (1.0%). The gender distribution is 
displayed in a pie chart at figure 4.6.  
 
Figure 0.6 Gender distribution for B. parapertussis infection 
 
 
 
 
1.49%
7.94%
2.63%
0.00%
13.04%
0.00%
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
14.00%
0 to 1 1 to 2 2 to 3 3 to 4 4 to 5 >5
Pe
rc
en
ta
ge
 
 
po
sit
iv
es
Age groups (Years)
  
4.0%
1.0%
B. parapertussis
Male
Female
 Chapter 4 Detection of Bordetella in respiratory specimens using multiplex PCR assays 106 
4.4 Detection of Bordetella holmesii 
Detection of B. holmesii was performed using the Bordetella multiplex PCR assay. 
462 clinical specimens were tested during the 1 year period and no positives (0.0%) 
were found. There was no culture method to detect B. holmesii in respiratory 
specimens in The Department of Microbiology at CHW. Therefore, the sensitivity 
and specificity were not compared to another method as with the other two 
Bordetella species. However, the PCR assay was shown to be very sensitive and 
specific, as described in section 3.3.5 and 3.3.6.  
   
4.5 Discussion 
In this one year study, 464 respiratory specimens were tested for B. pertussis, B. 
parapertussis and B. holmesii, in The Department of Molecular Pathology using the 
Bordetella multiplex PCR assay. The study found 13 positive cases (2.8%) of B. 
pertussis, 13 positive cases (2.8%) for B. parapertussis, 1 positive case of co-
infection of B. pertussis and B. parapertussis (0.2and no positive cases (0.0%) for B. 
holmesii.  
The sensitivity and specificity of the Bordetella multiplex PCR assay was compared 
with the Bordetella culture, with the sensitivity of 100.0% (95% CI= 51.0-100.0%) 
and the specificity of 98.3% (95% CI= 96.3-99.2%), for B. pertussis. The sensitivity 
of 100% (95% CI= 34.2-100%) and the specificity of 97.0% (95% IC= 95.6-98.8%) 
were determined for B. parapertussis. The sensitivity and specificity for B. holmesii 
was not performed due failure to detect any cases.   
The highest incidence of infection for both B. pertussis and B. parapertussis was 
found in January 2013. The an age range of Bordetella infection in this study was 
from 5 months to 11 years with the median age of 1.25 years. A higher incidence of 
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Bordetella infection occurred in the 3 to 5 years age group.  In this study, B. pertussis 
had a higher incidence  in females (4%) than males (1.6%) while B. parapertussis 
had a higher incidence in males (4%) than females (1%), however these numbers are 
two small to draw any conclusions about gender predominance.  
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Chapter 5 General discussion and conclusion 
5.1 Discussion 
Whooping cough remains an important respiratory disease associated with both 
vaccinated and unvaccinated children (45). Previous studies have found that the 3 
most common pathogens causing whooping cough are B. pertussis, B. parapertussis 
and B. holmesii (17).   
In this study, we have developed a very specific and sensitive multiplex PCR assay 
to detect these three major whooping cough causing Bordetella species. We found 25 
positive cases of Bordetella infection at CHW during the year 2013. Out of these, 12 
cases (48.0%) were positive of B. pertussis alone, 12 (48.0%) of B. parapertussis 
alone, 1 co-infected (4.0%) with B. pertussis and B. parapertussis and none (0.0%) 
B. holmesii. This was the first finding to our knowledge of the incidence of infection 
caused by these three Bordetella species, in an Australian paediatric hospital. The 
most important findings of this study were the 13 positive cases of B. parapertussis 
which were not diagnosed with the previous PCR method used at CHW, and no 
evidence of presence of B. holmesii in the paediatric cohort at CHW. Comparison of 
the incidence of infections caused by different Bordetella species around the world, 
are shown in table 5.1. However, this study, which represents the Australian 
population shows that B. parapertussis is also a major causative agent of whooping 
cough among children and B. holmesii is rare.  
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Table 0.1 Incidence of Infections and outbreaks of Bordetella species in other countries 
Country Study 
Year 
Method Targets Incident
s of B. 
pertussis 
(%) 
Incidents 
of B. 
parapertu
ssis (%) 
Incident
s of B. 
holmesii 
(%) 
Re
f 
This 
study 
Sydney/ 
Australia 
2013 End-
Point 
PCR 
IS481 
pIS1001 
hIS1001 
2.8 2.8 0 - 
Queensla
nd/ 
Australia 
(includin
g a 
suspecte
d B. 
pertussis 
outbreak
)  
1992-
1997 
Nested 
PCR 
IS481 
pIS1001 
 
11.2 1.3 N/A 66 
Ireland  2003-
2009 
Real-
Time 
PCR 
IS481 
pIS1001 
PtxP 
10.5 0.8 N/A 8 
Pakistan  2005-
2009 
Culture N/A 0 7.4 N/A 21 
 France  2003-
2005 
Real-
Time 
PCR 
IS481 
pIS1001 
16S 
rDNA 
14.4 2.3 N/A 64 
Denmark  2000-
2003 
End-
Point 
PCR  
IS481 
pIS1001 
PtxP 
16 2 N/A 6 
Minnesot
a 
/USA  
2001-
2009 
Real-
Time 
PCR 
IS481 
pIS1001 
 
8.1 2.7 N/A 65 
China  2002-
2004 
Real-
Time 
PCR 
IS481 
pIS1001 
PtxP 
6.7 1 N/A 15 
Japan 
(Outbrea
k 
investiga
tion) 
2010-
2011 
Real-
Time 
PCR 
IS481 
Rec A 
38.2 N/A 7.9 20 
Ohio/US
A 
(Outbrea
k 
investiga
tion) 
2010-
2011 
Real-
Time 
PCR 
IS481 
pIS1001 
hIS1001 
PtxA-Pr 
37.6% 
(29% out 
of all the 
IS481 
positive 
specimen
s) 
N/A 16.1 
(68% out 
of all the 
IS481 
positive 
specimen
s) 
16 
 Chapter 5 General discussion and conclusion 110 
Many diagnostic laboratories worldwide, including CHW, use the single target, 
IS481, in their PCR assay to detect B. pertussis DNA. However, this is not a very 
specific method to detect the causative agents of whooping cough. The presence of 
the IS481 sequence in multiple copies in the B. pertussis genome (50-238 copies per 
genome) is the potential advantage of this target by increasing the sensitivity of this 
PCR assay (17). However, this target sequence is present in B. holmesii as a low 
copy target sequence (8-10 copies per genome), which leads to additional specificity 
issues (17). Therefore, use of this insertion sequence alone may decrease the 
specificity of the PCR assay.  
In this study, we have used different targets for each of the Bordetella species to 
increase the specificity of the multiplex PCR assay as shown in table 5.2. The 
multiplex PCR assay was developed using one published primer and one primer 
developed in-house for all three Bordetella species and evaluated at CHW prior to 
the clinical study.    
 
Table 0.2 Target sequences for each Bordetella species used in multiplex PCR assay    
Bordetella species Target sequence Copy number per genome Ref 
B. pertussis IS481 50-238 63 
B. parapertussis pIS1001 20-21 46 
B. holmesii hIS1001 3-5 19 
  
Determination of the sensitivity and specificity of the Bordetella multiplex PCR 
assay compared to its comparable monoplex PCR assays and to Bordetella culture 
are summarised in table 5.3. Comparison of the performance of the multiplex PCR 
assay with bacterial culture allowed us to determine the most suitable diagnostic tool 
to be used as a routine diagnostic test at CHW.  This multiplex PCR assay was 
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shown to be a very sensitive, specific and efficient diagnostic tool to detect 
Bordetella infections at CHW.   
 
Table 0.3 Sensitivity and specificity of the Bordetella multiplex PCR assay compared to 
monoplex PCR assays and Bordetella culture. 
Bordetella multiplex PCR assay compared to monoplex PCR assays 
Bordetella Species Sensitivity Specificity 
B. pertussis(IS481) 100.0% 98.3% 
B. parapertussis (pIS1001) 100% 97.7% 
B. holmesii (hIS1001) ND ND 
Bordetella multiplex PCR assay compared to the  Bordetella culture 
B. pertussis 93.0% 100.0% 
B. parapertussis 100.0% 100.0% 
B. holmesii N/A N/A 
ND- Not Done, N/A- Not Applicable  
The limit of detection (LOD) for B. pertussis (IS481), B. parapertussis (pIS1001), 
and B. holmesii (hIS1001) were carried out to determine the individual performance 
of each Bordetella species within the multiplex PCR assay (see table 5.4).  
 
Table 0.4 LOD of the Bordetella multiplex PCR assay 
Bordetella Species/ Target sequence  CFU/ml 
B. pertussis/ IS481 0.20~1 
B. parapertussis/ pIS1001 0.22~1 
B. holmesii/ hIS1001 0.29~1 
 
The results of this experiment demonstrated a high performance for all three species 
of Bordetella in the multiplex PCR assay, and we were therefore able to successfully 
introduce this assay to the department of Molecular Pathology at CHW as a routine 
diagnostic test. 
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In this study, the incidence of infection for both B. pertussis and B. parapertussis 
was 2.8% and for B. holmesii, 0%. Furthermore, the rate of infection for B. pertussis 
was significantly lower than those reported from other countries (see table 5.1). This 
may be due to good childhood vaccination programmes conducted among Australian 
children, which may reflect changes in incidence of infection over time. B. 
parapertussis, however demonstrated a relatively high rate of infection, compared to 
the recent studies form other countries (see table 5.1). The reason for this result may 
be the lack of cross protection for B. parapertussis from the B. pertussis vaccine.      
According to the table 5.5, two of the specimens were not tested for B. holmesii due 
to insufficient quantity. Also one of the specimens out of 464 was positive for both 
B. pertussis and B. parapertussis. 
 
Table 0.5 Summery of the Bordetella infection in year 2013 
Bordetella 
species 
Total no of 
specimens 
tested 
No of 
positives 
Rate of 
infection 
Age of 
highest 
infection 
rate 
Gender 
distribution 
Male Female 
B. pertussis 464 13 2.8% 3-4 yr 1.6% 4% 
B. 
parapertussis 
464 13 2.8% 4-5yr 4% 1% 
B. holmesii 462 0 0.0% N/A N/A 
 
The most susceptible age group for Bordetella infection was found to be between 3-5 
years and, B. pertussis infection was more prominently appeared among girls and B. 
parapertussis was among boys, in this study.  
Further clinical sample testing is being carried by the technical staff of the 
department of Molecular Pathology at CHW, for the purpose of establishing the 
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pattern of infection and seasonal distribution over a three year period, from 2013-
2015.  
 
5.2 Conclusion  
This study was carried out in the molecular diagnostic laboratory and based on the 
paediatric population presented to CHW in 2013. We were able to develop a 
multiplex PCR assay to detect three major whooping cough causing Bordetella 
species which include B. pertussis, B. parapertussis and B. holmesii. After one year 
of successful clinical sample testing we were able to introduce this new methodology 
to the department of Molecular Pathology for routine diagnosis of Bordetella.  
The purpose of introducing Bordetella multiplex PCR assay was to provide faster 
and more sensitive diagnosis compared to the conventional Bordetella culture 
method, and to detect Bordetella infection caused by B. parapertussis and B. 
holmesii in one PCR assay, together with B. pertussis.  
 In conclusion, this study showed that B. parapertussis was one of the major 
causative agents of causing whooping cough in the Australian paediatric population 
similar to B. pertussis while B. holmesii was rare. Although there were no B. 
holmesii infections detected during the period of study, this assay can be used to 
detect B. holmesii in the future. 
The incidence of infection of B. pertussis was reduced in the year of study (2013), 
compared to the previous years. This may be due to the efficient immunisation 
programmes conducted among Australian children. B. parapertussis and B. holmesii 
cases were not detected or reported at CHW before this study year due to the absence 
of an effective and sensitive diagnostic method. The considerably high number of 
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reported cases of B. parapertussis in this study might be due to an absence of an 
effective vaccine for B. parapertussis, and lack of cross protection from existing B. 
pertussis vaccine. 
This study had very limited access to the clinical details of patients due to ethical 
considerations. Therefore, the clinical manifestations of the disease have not been 
elaborated in this study. Thus, this could be a great research opportunity for future 
studies. 
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